

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
23 August 2001 (23.08.2001)

PCT

(10) International Publication Number
WO 01/61012 A1

(51) International Patent Classification?: C12N 15/29,
15/82, 5/10, C12Q 1/68, C07K 14/415, A01H 5/00

c/o John Hopkins University, School of Medicine, 111
Market Place, Suite 906, Baltimore, MD 21202 (US).

(21) International Application Number: PCT/US00/35397

(74) Agent: KAGAN, Sarah, A.; Banner & Witcoff, Ltd.,
Eleventh Floor, 1001 G Street, N.W., Washington, DC
20001-4597 (US).

(22) International Filing Date:
28 December 2000 (28.12.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/183,333 18 February 2000 (18.02.2000) US

(63) Related by continuation (CON) or continuation-in-part
(CIP) to earlier application:
US 60/183,333 (CON)
Filed on 18 February 2000 (18.02.2000)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(71) Applicants and
(72) Inventors: NICOLAIDES, Nicholas, C. [US/US]; 4
Cider Mill Court, Boothwyn, PA 19061 (US). GRASSO,
Luigi [US/US]; 834 Chestnut Street, Apartment #816,
Philadelphia, PA 19107 (US). SASS, Philip, M. [US/US];
1903 Blackhawk Circle, Audubon, PA 19403 (US). KIN-
ZLER, Kenneth [US/US]; c/o John Hopkins University,
School of Medicine, 111 Market Place, Suite 906, Balti-
more, MD 21202 (US). VOGELSTEIN, Bert [US/US];

(54) Title: A METHOD FOR GENERATING HYPERMUTABLE PLANTS

(57) Abstract: Blockade of mismatch repair in a plant can lead to hypermutation and a new genotype and/or phenotype. One approach used to generate hypermutable plants is through the expression of dominant negative alleles of mismatch repair genes in transgenic plants or derived cells. By introducing these genes into cells and transgenic plants, new cell lines and plant varieties with novel and useful properties can be prepared more efficiently than by relying on the natural rate of mutation. Moreover, methods to inhibit the expression and activity of endogenous plant MMR genes and their encoded products are also useful to generate hypermutable plants.



WO 01/61012 A1

A METHOD FOR GENERATING HYPERMUTABLE PLANTS

This application claims the benefit of provisional application Serial No. 60/183,333, filed February 18, 2000.

TECHNICAL FIELD OF THE INVENTION

The invention is related to the area of mismatch repair genes. In particular it is related to the field of mutagenesis.

BACKGROUND OF THE INVENTION

Within the past four years, the genetic cause of the Hereditary Nonpolyposis Colorectal Cancer Syndrome (HNPCC), also known as Lynch syndrome II, has been ascertained for the majority of kindreds affected with the disease (1). The molecular basis of HNPCC involves genetic instability resulting from defective mismatch repair (MMR). To date, six genes have been identified in humans that encode proteins which appear to participate in the MMR process, including the *mutS* homologs *GTBP*, *hMSH2*, and *hMSH3* and the *mutL* homologs *hMLH1*, *hPMS1*, and *hPMS2* (2-7). Germline mutations in four of these genes (*hMSH2*, *hMLH1*, *hPMS1*, and *hPMS2*) have been identified in HNPCC kindreds (2-7).

Though the mutator defect that arises from the MMR deficiency can affect any DNA sequence, microsatellite sequences are particularly sensitive to MMR abnormalities (8,9). In addition to its occurrence in virtually all tumors arising in HNPCC patients, Microsatellite Instability (MI) is found in a small fraction of sporadic tumors with distinctive molecular and phenotypic properties (10).

HNPCC is inherited in an autosomal dominant fashion, so that the normal cells of affected family members contain one mutant allele of the relevant MMR gene (inherited from an affected parent) and one wild-type allele (inherited from the unaffected parent). During the early stages of tumor development, however, the wild-type allele is inactivated through a somatic mutation, leaving the cell with no functional MMR gene and resulting in a profound defect in MMR activity. Because a somatic

mutation in addition to a germ-line mutation is required to generate defective MMR in the tumor cells, this mechanism is generally referred to as one involving two hits, analogous to the biallelic inactivation of tumor suppressor genes that initiate other hereditary cancers. In line with this two-hit mechanism, the non-neoplastic cells of HNPCC patients generally retain near normal levels of MMR activity due to the presence of the wild-type allele (11-12).

While MMR is a conserved process found in bacteria, yeast, and mammalian cells (14-16), its activity has not been confirmed in plants. While sequences homologous to MMR genes have been identified in *Arabidopsis thaliana*, it is not known if they are functional in plants in the process of MMR (17-18). There is a need in the art for identification of the processes involved in genome stability in plants. There is a continuing need for methods and techniques for generating genetic diversity in agriculturally important crops.

SUMMARY OF THE INVENTION

It is an object of the invention to provide a method for making a hypermutable cell.

It is another object of the invention to provide a homogeneous composition of cultured, hypermutable, plant cells.

It is still another object of the invention to provide a hypermutable transgenic plant.

It is yet another object of the invention to provide a method for generating a mutation in a gene of interest in a plant cell.

It is still another object of the invention to provide a method for generating a mutation in a gene of interest in a plant.

It is an object of the invention to provide a method for generating a hypermutable plant.

It is another object of the invention to provide a vector for introducing a dominant negative MMR allele into a plant.

It is even another object of the invention to provide an

isolated and purified polynucleotide encoding a plant MutL homolog.

It is another object of the invention to provide an isolated and purified protein which is a plant MutL homolog.

It is an object of the invention to provide a method for determining the presence of a mismatch repair (MMR) defect in a plant or a plant cell.

These and other objects of the invention are provided by one or more of the following embodiments. In one embodiment of the invention a method for making a hypermutable cell is provided. A polynucleotide comprising a dominant negative allele of a mismatch repair gene is introduced into a plant cell, whereby the cell becomes hypermutable.

In another aspect of the invention a homogeneous composition of cultured, hypermutable, plant cells is provided. The plant cells comprise a dominant negative allele of a mismatch repair gene.

Another aspect of the invention is a hypermutable transgenic plant. At least 50% of the cells of the plant comprise a dominant negative allele of a mismatch repair gene.

According to another aspect of the invention a method is provided for generating a mutation in a gene of interest in a plant cell. A hypermutable plant cell comprising the gene of interest and a dominant negative allele of a mismatch repair gene is grown. The cell is tested to determine whether the gene of interest harbors a newly acquired mutation.

Another embodiment of the invention is a method for generating a mutation in a gene of interest in a plant. A plant comprising the gene of interest and a polynucleotide encoding a dominant negative allele of a mismatch repair gene is grown. The

plant is tested to determine whether the gene of interest harbors a newly acquired mutation.

According to another aspect of the invention a method is provided for generating a hypermutable plant. Endogenous mismatch repair (MMR) activity of a plant is inhibited. The plant becomes hypermutable as a result of the inhibition.

Another aspect of the invention is a vector for introducing a dominant negative MMR allele into a plant. The vector comprises a dominant negative MMR allele under the transcriptional control of a promoter which is functional in a plant.

Still another aspect of the invention provides an isolated and purified polynucleotide encoding *Arabidopsis thaliana* PMS2 as shown in SEQ ID NO: 14.

Another aspect of the invention provides an isolated and purified polynucleotide encoding *Arabidopsis* PMS134 as shown in SEQ ID NO: 16.

According to another embodiment of the invention an isolated and purified protein which is *Arabidopsis* PMS2 is provided. It has the amino acid sequence as shown in SEQ ID NO: 14.

Another embodiment of the invention is an isolated and purified protein which is *Arabidopsis* PMS134. It has the amino acid sequence as shown in SEQ ID NO: 16.

Still another aspect of the invention provides a method for determining the presence of a mismatch repair (MMR) defect in a plant or a plant cell. At least two microsatellite markers in test cells or a test plant are compared to the at least two microsatellite markers in cells of a normal plant. The test plant or plant cells are identified as having a mismatch repair defect if at least two microsatellite markers are found to be rearranged relative to the cells of the normal plant.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1. Alignment of the Arabidopsis thaliana and human PMS2 cDNAs.

Fig. 2. Alignment of the Arabidopsis thaliana and human PMS2 proteins.

Fig. 3. Alignment of the Arabidopsis thaliana MLH1 homolog and the human PMS2 proteins.

Fig. 4. Alignment of the Arabidopsis thaliana PMS1 homolog and the human PMS2 proteins.

Fig. 5. Phylogenetic tree of Arabidopsis thaliana MutL homologs and the human PMS2 protein.

Fig. 6. Alignment of the Arabidopsis thaliana PMS134 and the human PMS134 cDNA.

Fig. 7. Alignment of the Arabidopsis thaliana PMS134 and the human PMS134 polypeptides.

Fig. 8. Western blot analysis of bacteria expressing the hPMS134 (Fig. 8A) or the Arabidopsis thaliana PMS134 (Fig. 8B) polypeptides.

Fig. 9. Expression of plant dominant negative MMR genes produces hypermutability in bacteria, demonstrating the functionality of plant MMR proteins.

Fig. 10. Schematic diagram of a plant dominant-negative MMR expression vector.

Fig. 11. Transgenic plants containing the PMS134-KAN vector express the dominant negative hPMS134 gene.

Fig. 12. Microsatellite instability in plants expressing dominant negative MMR hPMS134 gene.

Fig. 13. MMR defective plants produce new phenotypes. Plants with decreased MMR produce offspring with two shoot apical meristems (SAM) in contrast to control plants exhibiting a single SAM.

DETAILED DESCRIPTION OF THE INVENTION

It is a discovery of the present inventors that plant cells have functional mismatch repair (MMR) systems which function similarly to mammalian MMR. Moreover, dominant negative alleles can be made and used to generate variability in plants and plant cells, as in mammalian cells.

Other means of interfering with normal MMR activity can also be used as described in detail below. Dominant negative alleles of mismatch repair genes, when introduced into cells or plants, increase the rate of spontaneous or induced mutations by reducing the effectiveness of DNA repair and thereby render the cells or whole organism hypermutable. Hypermutable plant cells or plants can be utilized to develop new mutations in a gene of interest.

The process of mismatch repair, also called mismatch proofreading, is carried out by protein complexes in cells ranging from bacteria to mammalian cells (9, 14-16). A mismatch repair (MMR) gene is a gene that encodes one of the proteins of a mismatch repair complex. Although not wanting to be bound by any particular theory or mechanism of action, a mismatch repair complex is believed to detect distortions of a DNA helix resulting from non-complementary pairing of nucleotide bases. The non-complementary base on the newer DNA strand is excised, and the excised base is replaced with the appropriate base, which is complementary to the older DNA strand. In this way, cells eliminate many mutations which occur as a result of mistakes in DNA replication.

For purposes of example, this application discloses use of dominant negative alleles of MMR genes as a method for blocking or inhibiting MMR activity in plants. (Blocking or inhibiting are used synonymously herein, and denote any significant level of inhibition. They do not connote complete inhibition, although the terms include that possibility within their ambit.) However, any molecular method known by those skilled in the art to block MMR gene expression and/or function can be used, including but not limited to gene knockout (19), antisense technology (20), double stranded RNA interference (21), and polypeptide inhibitors (22).

Dominant negative alleles cause a mismatch repair defective phenotype even in the presence of a wild-type allele in the same cell. An example of a dominant negative allele of a mismatch repair gene is the human gene *hPMS2-134*, which carries a truncation mutation at codon 134 (13, U.S. Patent No. 6,146,894). The mutation causes the product of this gene to prematurely terminate at the position of the 134th amino acid, resulting in a shortened polypeptide containing the N-terminal 133 amino acids. Such a mutation causes an increase in the rate of mutations which accumulate in cells after DNA replication. Expression of a dominant negative allele of a mismatch repair gene results in impairment of mismatch repair activity, even in the presence of the wild-type allele. Any allele which produces such effect can be used in this invention.

Dominant negative alleles of a mismatch repair gene can be obtained from the cells of humans, animals, yeast, bacteria, plants or other organisms as described by Nicolaides et. al. (23) and Hori et. al. (24). Alternatively such alleles can be made from wild-type alleles, typically by inserting a premature stop codon or other mutation which leads to a protein product which is able to complex with other members of the MMR complex but which is not functional. Such alleles can be identified by screening cells for defective mismatch repair activity. The cells may be mutagenized or not. Cells from plants exposed to chemical mutagens or radiation, e.g., can be screened for defective mismatch repair. Genomic

DNA, a plasmid containing cDNA, or mRNA from any cell encoding a mismatch repair protein can be analyzed for variations from the wild type sequence. Dominant negative alleles of a mismatch repair gene can also be created artificially, for example, by producing variants of the *hPMS2-134* allele or other mismatch repair genes (13, U.S. Patent No. 6,146,894). Other truncated alleles of *PMS2* or other MMR genes can be made. Such alleles are expected to behave similarly to *hPMS2-134*. An of various forms of site-directed mutagenesis can be used. The suitability of such alleles, whether natural or artificial, for use in generating hypermutable cells or plants can be evaluated by testing the mismatch repair activity caused by the allele in the presence of one or more wild-type alleles, to determine if the allele is dominant negative.

A cell or a plant into which a dominant negative allele of a mismatch repair gene has been introduced will become hypermutable. This means that the mutation rate (spontaneous or induced) of such cells or plants is elevated compared to cells or plants without such alleles. The degree of elevation of the mutation rate can be at least 2-fold, 5-fold, 10-fold, 20-fold, 50-fold, 100-fold, 200-fold, 500-fold, or 1000-fold that of the normal cell or plant.

According to one aspect of the invention, a polynucleotide encoding a dominant negative form of a mismatch repair protein is introduced into a cell or a transgenic plant. The gene can be any dominant negative allele encoding a protein which is part of a mismatch repair complex, for example, *mutS* or *mutL* homologs of the bacterial, yeast, fungal, insect, plant, or mammalian genes. The dominant negative allele can be naturally occurring or made in the laboratory. The polynucleotide can be in the form of genomic DNA, cDNA, RNA, or a chemically synthesized polynucleotide. The polynucleotide can be introduced into the cell by transfection.

Transfection is any process whereby a polynucleotide is introduced into a cell. The process of transfection can be carried out in a living plant,

e.g., using a binary vector for gene transmission, or it can be carried out *in vitro*, *e.g.*, using a suspension of one or more isolated cells in culture. The cell can be any type of plant cell.

In general, transfection can be carried out using a suspension of cells, or a single cell, but other methods can also be used as long as a sufficient fraction of the treated cells incorporates the polynucleotide to allow transfected cells to be readily isolated. The protein product of the polynucleotide may be transiently or stably expressed in the cell.

Techniques for transfection are well known in the art of plant cell science. Available techniques for introducing polynucleotides include but are not limited to electroporation, transduction, *Agrobacterium*-mediated gene transfer, cell fusion, the use of calcium chloride, and packaging of the polynucleotide together with lipid for fusion with the cells of interest. Once a cell has been transfected with the mismatch repair gene, the cell can, *e.g.*, be grown and reproduced in culture. If the transfection is stable, such that the gene is expressed at a consistent level for many cell generations, then a cell line results. Alternatively, a dominant negative MMR protein can be directly introduced by microinjection into a cell in order to inhibit MMR activity of the cell.

Root explants are incubated in 0.5 ug/ml of 2-4-dichlorophenoxy-acetic acid (2-4D) plus N6-Benzyl-Adenine in growth medium. After 4 weeks, suspension cells are isolated and digested with hemicellulase for protoplast preparation and transfection. Such isolated cells are typically cultured in the absence of other types of cells. Cells selected for the introduction of a dominant negative allele of a mismatch repair gene may be derived from a multicellular plant in the form of a primary cell culture or an immortalized cell line, or may be derived from suspensions of single-celled plants.

A polynucleotide encoding a dominant negative form of a mismatch repair protein can be introduced into the genome of a plant to form a transgenic plant. The plant can be any species for which suitable

techniques are available to produce transgenic plants. For example, transgenic plants can be prepared from domestic agricultural crops, *e.g.* corn, wheat, soybean, rice, sorghum, barley, etc.; from plants used for the production of recombinant proteins, *e.g.*, tobacco leaf; or experimental plants for research or product testing, *e.g.*, *Arabidopsis*, pea, *etc.* The introduced polynucleotide may encode a protein native to the species or native to another species, whether plant, animal, bacterial, or fungal, for example.

Any method for making transgenic plants known in the art can be used. According to one process of producing a transgenic plant, the polynucleotide is transfected into the plant seedling. The seed is germinated and develops into a mature plant in which the polynucleotide is incorporated and expressed. An alternative method for producing transgenic plants involves introducing the polynucleotide into the growing or mature plant by injection, electroporation, *Agrobacterium*-mediated transfer or transfection. With this method, if the polynucleotide is not incorporated into germline cells, the gene will not be passed on to the progeny. Therefore, a transgenic plant produced by this method will be useful to produce products from that individual plant.

To identify whether a gene was inserted into the germline, seedlings derived from such plants can be screened for the transgene. Genetic modification of a growing or mature plant is useful for evaluating the expression of hypermutable constructs and for evaluating effects on altering endogenous mismatch repair. Once transgenic plants are produced, they can be grown to produce and maintain a crop of transgenic plants.

Once a transfected cell line or a crop of transgenic plants has been produced, it can be used to generate new mutations in one or more gene(s) of interest. A gene of interest can be any gene naturally possessed by the cell line or transgenic plant or introduced into the cell line or transgenic plant. An advantage of using MMR-defective cells or plants to induce mutations is that the cell or plant need not be exposed to mutagenic

chemicals or radiation, which may have secondary harmful effects, both on the object of the exposure and on the workers.

Mutations can be detected by analyzing the genotype of the cells or plants, for example by examining the sequence of genomic DNA, cDNA, messenger RNA, or amino acids associated with the gene of interest. Mutations can also be detected by testing a phenotype caused by the gene. A mutant phenotype can be detected, *e.g.*, by identifying alterations in electrophoretic mobility, spectroscopic properties, or other physical or structural characteristics of a protein encoded by a mutant gene. One can also screen for altered function of the protein *in situ*, in isolated form, or in model systems. One can screen for alteration of any property of the cell or plant associated with the function of the gene of interest or its protein product. Finally, one can screen for macroscopic phenotypes such as but not limited to color, height, or the ability to grow in drought, high-salt, cold, hot, acidic, basic, pest-infested, or high ethylene environments.

The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific examples that will be provided herein for purposes of illustration only, and are not intended to limit the scope of the invention.

EXAMPLE 1: Isolation of Plant Mismatch Repair Genes.

The ability to increase the hypermutability of host genomes has many commercial and medical applications. The generation of hypermutable plants such as those used in agriculture for livestock feed and human consumption are just one example of many types of applications that can be generated by creating hypermutable organisms. For instance, the creation of crops that are less susceptible to pests or soil pH would greatly increase yield of certain agricultural crops. In addition to greater production of goods, improved crops could increase the ability to grow many generations of crops on the same fields (25-27). Moreover, the

ability to affect certain growth traits such as natural pest-resistance, drought-resistance, frost-resistance, increased production, or altered stalk size has many benefits for the production of agricultural products. Recently, it has been demonstrated that genes affecting the biologic activity of the plant growth hormone gibberellin results in crops with shorter stalk length that produce similar amounts of grain yields, however, the fact that the stalks are shorter makes these plants less susceptible to high winds and crop damage (28). The use of hypermutable crops could allow for the selection of shorter plants across many species such as corn, rice, etc, without having to first identify a gene to alter its activity. Another application of hypermutable agricultural products is the generation of crops with enhanced levels of vitamins and nutrients. One can select for enhanced vitamin production in seedlings of MMR defective plants. Recently, it has been demonstrated that altering a gene(s) within a vitamin biosynthetic pathway can result in the production of elevated levels of vitamin E (27,29).

Applications of hypermutable plants include use as crops for agricultural production, increased medicinal entities within plant extracts, chemicals and resins for industrial use, and their use as detoxifying organisms for environmental applications as described (25,26,29).

MutS and mutL homologs can be isolated from plant species libraries using degenerate RT-PCR, and standard Southern hybridization techniques as previously described (3,23,30). These may serve as reagents for producing MMR defective plant hosts. This process employs methods known by those skilled in the art of gene cloning.

One such approach is the use of degenerate PCR to clone MutS homologs following the methods used by Leach et. al. to clone the human MSH2 (3). Additional degenerate oligonucleotides can be generated and used against conserved domains of bacterial, yeast, and human MutS homologs. Various plant species cDNAs (obtainable from various commercial sources) can be amplified for MutS gene homologs by

polymerase chain reaction (PCR). Products are cloned into T-tailed vectors (In Vitrogen) and analyzed by restriction endonuclease digestion. Clones with expected DNA fragment inserts are sequenced using M13 forward and reverse primers located on the vector backbone flanking the cloning site.

Fragments containing MMR gene homologs are then used as probes to screen commercially available cDNA libraries from the appropriate species.

cDNA contigs are generated to create a cDNA containing the sequence information for the full length MMR gene and its encoded polypeptide.

One such example of cloning a plant MMR gene is provided below.

In order to clone *mutL* homologs, degenerate primers were synthesized to the conserved domains of the *mutL* gene family by aligning *E. coli*, yeast, mouse, and human *mutL* genes. These primers are directed to the polynucleotide sequences centered at nt 150 to 350 of the published human PMS2 cDNA (SEQ ID NO: 3). Degenerate PCR was carried out using RNA from *Arabidopsis thaliana* (AT) that was isolated using the RNeasy kit following the manufacturer's protocol (Qiagen). RNAs were reverse transcribed (RT) using SuperscriptII (Life Technologies) following the manufacturer's protocol. After RT, cDNAs were PCR amplified using degenerate primers in buffers described by Nicolaides et. al. 1995 (23,30), and reactions were carried out at 95°C for 30 sec for 1 cycle followed by 94°C for 30 sec, 45°C for 60 sec, and 72°C for 60 sec for 20 cycles. PCR reactions were then diluted 1:10 in water and reamplified using the same primers and buffers. The secondary PCR reactions were carried out at 95°C for 30 sec for 1 cycle followed by 94°C for 30 sec, 52°C for 90 sec, and 72°C for 90 sec for 35 cycles. Reactions were analyzed by agarose gel electrophoresis. Products of the expected molecular weight were excised and cloned into T-tailed vectors (InVitrogen). Recombinant clones were sequenced and blasted against the public databases. The homolog was found to have homology to the *mutL* family of genes. Blast search analysis of GenBank found this gene to be part of a "putative" mismatch repair gene identified from the *Arabidopsis* genome project that has never been

reported to be transcribed or capable of producing a message. In order to clone the full length, an Arabidopsis cDNA library was screened by PCR as well as cDNA from AT plants using 5' primers corresponding to the initiation codon (SEQ ID NO: 1: 5'-atg caa gga gat tct tc-3') and the termination codon (SEQ ID NO: 2: 5'-tca tgc caa tga gat ggt tgc-3') using buffers and conditions listed above. Amplifications were carried out at 95°C for 30 sec for 1 cycle followed by 94°C for 30 sec, 58°C for 2 min, and 72°C for 3 min for 35 cycles. Products were analyzed by gel electrophoresis. Products of the expected molecular weights were subcloned into T-tail vectors and sequenced using primers from the cloning vector or using internal primers. Figure 1 shows the alignment of one Arabidopsis homolog, referred to as *ATPMS2* (SEQ ID NO: 4), to the human *PMS2* cDNA (SEQ ID NO:3) (Fig. 1) and the hPMS2 protein (Fig. 2; SEQ ID NO:13). This gene was found to be homologous (48% identity) to the human *PMS2* (SEQ ID NO:3) cDNA and its encoded polypeptide (31% identity) (Figure 2). Other homologs to the *ATPMS2* were also identified from blast searching sequence databases. One mutL homolog is closely related to the MLH1 mammalian homolog and is referred to as ATMLH1 (shown in Fig. 3) and another is closely related to the mammalian PMS1 polypeptide referred to as ATPMS1 (shown in Fig. 4). A phylogenetic tree is shown in Fig. 5 showing the homology of the mutL homologs to the human *PMS2* gene.

Degenerate primers can be used for isolating MMR genes from other plant species in a similar fashion.

EXAMPLE 2: Generation Of Dominant Negative Alleles Of Plant Mismatch Repair Genes

To demonstrate that putative plant MMR proteins are truly involved in MMR biochemical process, cDNAs are cloned into constitutive (31,32) or inducible (33) bacterial expression vectors for functional studies.

Various deletion mutants are generated to produce dominant negative MMR genes. Dominant negative alleles that are identified in the bacterial system are then useful for plant studies. Dominant negative MMR genes are prepared by over-expression of full-length MMR genes or by deletion analysis using standard protocols used by those skilled in the art of molecular biology. One such dominant MMR gene mutant was created by generating a construct with similar domains to that of the human dominant negative PMS2 gene (referred to as PMS134) (13, U.S. Patent No. 6,146,894). To generate this vector, the ATPMS2 (SEQ ID NO: 4) and hPMS2 cDNA (SEQ ID NO: 3) sequences were aligned and the conserved domain was isolated. Figure 6 shows a sequence alignment between the human and AT PMS134 cDNAs where a 52% identity is found between the two sequences. At the protein level these domains have a 51% identity (Figure 7). Dominant negative hPMS134 and ATPMS134 genes were made by PCR and subcloned into bacterial expression vectors. The ATPMS134 was generated by PCR from the cloned cDNA using a sense primer (SEQ ID NO: 1) corresponding to the N-terminus and an antisense primer (SEQ ID NO: 5), 5'-gtcgacttatcacttgcatcgtcgtcctttagtcgagcgtagc-aactggctc-3' centered at nt 434 of the ATPMS2 cDNA (SEQ ID NO: 4). This primer also contains a flag epitope that will allow protein detection followed by two termination codons. PCR products of the expected molecular weight were gel purified and cloned into T-tail vectors. Recombinant clones were sequenced to ensure authentic sequences. Inserts were then cloned into the inducible pTAC expression vector, which also contains the Ampicillin resistance gene as a selectable marker. The human PMS134 allele was also cloned into the pTAC expression vector as a positive control. Electrocompetent DH5alpha and DH10b bacterial cells (Life Technologies) were electroporated with empty vector, and the loaded vectors pTACATPMS134 and pTACHPMS134, using an electroporator (BioRad) following the manufacturer's protocol. Bacterial cultures were then plated on to LB agar plates containing 100µg/ml ampicillin and grown

at 37°C for 14 hours. Ten recombinant clones were then isolated and grown in 5 mls of LB broth containing 50 µg/ml ampicillin plus 50µM IPTG for 18 hr at 37°C. One hundred microliters were then collected, spun down, and directly lysed in 2X SDS buffer for western blot analysis. For western analysis, equal number of cells were lysed directly in 2X SDS buffer (60 mM Tris, pH 6.8, 2% SDS, 10% glycerol, 0.1 M 2-mercaptoethanol, 0.001% bromophenol blue) and boiled for 5 minutes. Lysate proteins are separated by electrophoresis on 4-12% NuPAGE gels (Novex). Gels are electroblotted onto Immobilon-P (Millipore) in 48 mM Tris base, 40 mM glycine, 0.0375% SDS, 20% methanol and blocked overnight at 4°C in Tris-buffered saline plus 0.05% Tween-20 and 5% condensed milk. Filters are probed with a polyclonal antibody generated against MMR polypeptide sequence or a fused tag (e.g. FLAG, HIS, etc.) and a horseradish peroxidase conjugated secondary antibody, using chemiluminescence for detection (Pierce). Figure 8 shows a western blot of a clone that expresses the human PMS134 protein (Figure 8A, lane 2) using a human PMS2-specific antibody (directed to residues 2-20) of the hPMS134 sequence (see Fig. 1, and SEQ ID NO:6) or the Arabidopsis PMS134 protein (Figure 8B, lane 2) using an anti-FLAG antibody directed to the fusion residues at the C-terminus of the protein. Cells expressing empty vector had no detectable expression.

Bacterial clones expressing the *hPMS134*, *ATPMS134* or the empty vector were grown in liquid culture for 24 hr at 37°C in the presence of 50 µg/ml ampicillin plus 50µM IPTG. The next day, cultures were diluted 1:10 in medium containing 50µM IPTG plus ampicillin or ampicillin plus 25 µg/ml kanamycin (AK) and cultures were grown for 18 hr at 37°C. The following day, a 0.1 µl aliquot (2 µl diluted in 1000 µl of LB medium and used 50 µl for plating) of cells grown in Amp medium were plated on LB-agar plates containing 40 µg/ml of 5-bromo-4-chloro-3-indolyl-B-D-galactoside (X-gal) plus 100µg/ml ampicillin (AMP), while a 1 µl aliquot (1 µl diluted in 100 µl of LB medium and used 100 µl for plating) of cells

grown in AK medium were plated on LB-agar plates containing X-gal and 50µg/ml kanamycin (KAN). Plates were incubated for 18 hours at 37°C. The results from these studies show that cells expressing the hPMS134 or the ATPMS134 polypeptides displayed increased mutation rates in the genome of the DH10B bacterial strain which resulted in the production of KAN resistant clones (Figure 9). Following the mutagenesis protocol described above, bacterial cells expressing the plant ATPMS134 were found to have an increase in the number of KAN resistant cells (12 clones) in contrast to cells expressing the empty vector, which yielded no KAN resistant clone. These data demonstrate that dominant negative *ATPMS134* MMR genes are useful for creating hypermutable organisms that can generate phenotypically diverse offspring when put under selective conditions. Moreover, these data demonstrate that plants also use the conserved MMR process for genomic stability.

Dominant negative plant MMR gene mutants are also analyzed using mammalian cell systems. In this case, plant MMR gene cDNAs are cloned into eukaryotic expression vectors as described (13,34) and cells expressing dominant negative mutants are analyzed by measuring stability of endogenous microsatellite markers and biochemical activity of cell extracts from lines expressing dominant negative MMR gene alleles. Such methods are known by those skilled in the art and previously described (13).

EXAMPLE 3: Inhibition Of Plant MMR Activity By Dominant Negative MMR Alleles Produces Genetic Hypermutable And Microsatellite Instability.

Dominant negative alleles of human and AT MMR genes identified using bacterial and or mammalian systems can be used for plants. To test the hypothesis that dominant negative MMR gene

alleles produce global hypermutability in plants, the hPMS134 and ATPMS134 cDNAs were expressed in plants. These alleles have been found to work across species where the introduction of these genes into MMR proficient bacterial or mammalian cells renders the cells MMR deficient. Assays to carry out these studies are described below.

Engineering plant expression vectors to express the PMS134 dominant negative alleles.

A BamH I fragment containing the hPMS134 cDNA was obtained from the pSG5PMS134 plasmid (ref 13) and cloned into the corresponding sites of the pEF1/SP1-V5 vector (Invitrogen). The resulting vector (pEF-PMS134-sense) was then digested with Pme I to release a blunted DNA fragment containing the PMS134 cDNA. This fragment was then subcloned into the blunt Sma I and EcoICR I sites of the pGPTV-KAN binary plant expression vector (American Type Culture Collection). One clone, named pCMV-hPMS134-Kan (see figure 10), was sequenced to confirm that the vector contained authentic promoter and gene insert sequences. A schematic diagram of the pCMV-hPMS134-Kan vector is shown in Figure 10.

Generation of hPMS134-Expressing Arabidopsis thaliana transgenic plants.

Agrobacterium tumefaciens cells (agrobacteria) are used to shuttle genes into plants. To generate PMS134-expressing Arabidopsis thaliana (*A. thaliana*) plants, *Agrobacterium tumefaciens* cells (strain GV3101) were electroporated with pCMV-hPMS134-Kan or the pBI-121 (BRL) control binary vector. The pBI-121 control contains the CaMV promoter driving the expression of the β -glucuronidase cDNA (GUS) and serves as a control.

Both vectors carry the neomycin phosphotransferase (NPTII) gene that allows selection of agrobacteria and plants that contain the expression vector. One-month old *A. thaliana* (ecotype Columbia) plants were infected

by immersion in a solution containing 5% sucrose, 0.05% silwet, and binary vector-transformed agrobacteria cells for 10 seconds. These plants were then grown at 25°C under a 16 hour day and 8 hour dark photoperiod. After 4 weeks, seeds (referred to as T1) were harvested and dried for 5 days at 4°C. Thirty thousands seeds from ten CMV-hPMS134-Kan-transformed plants and five thousand seeds from two pBI-121-transformed plants were sown in solid Murashige and Skoog (MS) media plates in the presence of 50 µg/ml of kanamycin (KAN). Three hundred plants were found to be KAN resistant and represented PMS134 expressing plants. These plants along with 300 control plants were grown in MS media for two weeks and then transferred to soil. Plants were grown for an additional four weeks under standard conditions at which time T2 seeds were harvested.

To confirm the integration and stability of the PMS134 gene in the plant genome, gene segregation and PCR analyses were conducted. Commonly, three out of four T1 plants transformed by agrobacteria technology are expected to carry the vector inserted within a single locus and are therefore considered heterozygous for the integrated gene.

Approximately 75% of the seeds (T2) generated from most of the T1 plants were found KAN-resistant and this in accordance with the expected 1:2:1 ratio of null (no hPMS134 containing plants), heterozygous, and homozygous plants, respectively, in self-pollinating conditions. To confirm that these plants contained the hPMS134 expression vector, genomic DNA was isolated from leaves of T1 plants using the DNAzol-mediated technique following the manufacturer's suggestion (BRL-Life Technologies). One nanogram of genomic DNA was analyzed by polymerase chain reaction (PCR) to confirm the presence of the hPMS134 gene. PCR was carried out for 25 cycles with the following parameters: 95°C for 30 seconds; 55°C for 1 minute; and 72°C for 2 minutes using hPMS134-specific sense (SEQ ID NO: 7: 5'-tct aga cat gga gcg agc tga gag ctc-3') and antisense (SEQ ID NO: 8: 5'-tct aga agt tcc aac ctt cgc cga tgc-3') primers. Positive reactions were observed in DNA from pCMV-

hPMS134-Kan-transformed plants and not from pBI-121-transformed plants, thus confirming the integration of this vector.

In order to assess the expression of hPMS134 in T1 plants, leaf tissue was collected from T1 plants, homogenized in liquid nitrogen using glass pestles, and suspended in RLT lysing buffer (Qiagen, RNeasy plant RNA extraction kit). Five micrograms of total RNA was purified according to the manufacturer's suggested protocol and then loaded onto a 1.2% agarose gel (1x MOPS buffer, 3% formaldehyde), size-fractionated by electrophoresis, and transferred onto N-Hybrid+ membrane (Amersham). Each membrane was incubated at 55°C in 10 ml of hybridization solution (North2South labeling kit, Pierce) containing 100 ng of PMS134, tubulin, or KAN cDNA probes, which were generated by PCR amplification, according to the manufacturer's directions. Membranes were washed three times in 2x SSC, 0.1% SDS at 55°C, and three times in 2x SSC at ambient temperature. Detection was carried out using enhanced chemiluminescence (ECL). Expression was also carried out by reverse transcriptase PCR as described above using polyA isolated mRNA that was isolated over a oligo dT column (Qiagen). A representative example of these studies are shown in figure 11. Here hPMS134 expression was detected in three out of ten analyzed pCMV-hPMS134-Kan transgenic lines, while no signal was found in the ten pBI-121 transformed plants analyzed. Immunoblot using whole lysates is used to confirm protein expression. Collectively these studies demonstrate the generation of hPMS134 expressing transgenic *A. thaliana* plants.

Molecular Characterization of PMS134-Expressing Plants.

MMR is a process that is involved in correcting point mutations and "slippage" mutations within repetitive mono-, di-, and tri-nucleotide (microsatellite) repeats that occur throughout the genome of an organism after cellular replication. This process is very similar to a computer spell

check function. The inactivation of MMR has been shown to result in global genomic hypermutation whereby cells with defective MMR experience over a one thousand-fold increase in point mutations and microsatellite instability (MI) (mutations within repetitive sequences) throughout their genomes per division. (35). MMR deficiency is the only known process capable of producing MI and has been used as a marker to detect cells with MMR dysfunction (36). Microsatellites serve as molecular tools to measure the inactivation of MMR that occurs by the defective MMR due to but not limited to expression of dominant negative MMR genes, double stranded RNA interference vectors, or inhibition by antisense nucleotides, or by gene knockout. In *A. thaliana*, a series of poly-A (A)_n, (CA)_n and (GA)_n sequences were identified from genome searches using EMBL and GenBank databases. To demonstrate that hPMS134 expression could produce MI in *A. thaliana*, we analyzed microsatellites in T1 plants by PCR analyses. Initially we monitored three microsatellites, ATHACS, Nga280, and Nga128 with published primers that have been previously used to map the Arabidopsis genome (37). Briefly, DNA was extracted from *A. thaliana* leaves as described above. 10 ngs of plant genomic DNA was used as template for PCR amplification using the following amplification conditions: 94°C for 15 sec, 55°C for 15 sec and 72°C for 30 seconds. PCR products were analyzed on 5% Metaphor agarose (BioWhittaker Molecular Applications) and ethidium bromide staining. In one transgenic pCMV-PMS134-Kan line, we detected a double product, likely representing a new allele of the polymorphic nga280 locus (Figure 12). These data demonstrate the ability to produce MMR deficiency and MI in plants expressing the hPMS134 dominant negative allele and provide a molecular tool for screening MMR-defective plants.

Biochemical assays for mismatch repair. MMR activity in nuclear extracts is performed as described, using 24 fmol of substrate as described (13). Complementation assays are done by adding ~ 100 ng of purified MutL or MutS components to 100 µg of nuclear extract, adjusting the final

KCl concentration to 100 mM. The substrates used in these experiments will contain a strand break 181 nucleotides 5' or 125 nucleotides 3' to the mismatch.

EXAMPLE 4: Inactivation Of MMR Leads To Plants With New Phenotypes.

We demonstrated the ability of the defective MMR to produce molecular changes within plants. The objective of this section is to demonstrate the ability to generate MMR defective plants with macroscopic output traits. One way to measure for plants with new phenotypes is to grow plants under toxic conditions, such as but not limited to high levels of toxic ions, pest-infection, drought conditions, or extreme temperatures to identify a minority of plants with new output traits, *i.e.*, resistance. Another way to score for plants with new phenotypes is through physical differences of MMR defective plants grown in standard conditions. An example of MMR-defective plants with new phenotypes include the generation of plants with double shoot apical meristems (Figure 13) as well as plants with altered chlorophyll production rendering plants albino (data not shown). In Figure 13, we show a typical wild type plant (left, labeled normal) and a plant produced from the MMR defective group (right, labeled MMR deficient). The double-meristem trait was not observed in greater than 500 normal plants. The double-meristem trait does not appear to be due to transgene integration since segregation analysis reveals the ability to generate double-meristem plants in the absence of transgene positive plants while MMR proficient control plants with other transgene vectors (pBI-121) did not produce this phenotype (data not shown). These data suggest that defective MMR produced a mutation or mutations within the plant genome that altered the normal biochemical function of the host to produce a new output trait.

These data demonstrate the ability to create plant subtypes with new

genetic and phenotypic traits by blocking the endogenous MMR process of the plant cell or whole organism.

EXAMPLE 5: Inhibition of Plant MMR Activity Using Molecular Approaches.

This application teaches of the use of inhibiting MMR activity in a plant to produce genetically altered offspring with new phenotypes.

The inhibition of MMR activity in a host organism can be achieved by introducing a dominant negative allele as shown in Figure 11 and 12. Other ways to suppress MMR activity of a host is by: knocking out alleles of a MMR protein through homologous recombination (38); blocking MMR protein dimerization with other subunits (which is required for activity) by the introduction of polypeptides into the host via transfection methods; knocking out the expression of a MMR gene using anti-sense oligonucleotides (20), and/or the use of double stranded RNA interference genes, (21).

MMR gene knockouts.

Data shown in EXAMPLE 1 demonstrate that plants contain MMR gene homologs that can be genetically engineered to produce altered biochemical activities. Data presented in EXAMPLES 3 and 4 demonstrate that defective MMR in plants can produce hypermutable parental plants and offspring. Together, these data demonstrate that inhibiting endogenous MMR genes by targeting vectors of the particular MMR gene can lead to hypermutability of a plant host that generate offspring with altered genetic loci and/or new phenotypes as described in EXAMPLES 3, 4, and 5. Hypermutable seedlings can also be produced with "knocked out" MMR genes using methods known by those skilled in the art. These can be used to produce genetically diverse offspring for commercial and medical

applications (38). Cells will be confirmed to have lost the expression of the MMR gene using standard northern techniques and determined to be MMR defective using microsatellite analysis as described in EXAMPLE 3.

Blocking polypeptides.

MMR subunits (MutS and MutL proteins) interact to form active MMR complexes. Peptides are able to specifically inhibit the binding of two proteins by competitive inhibition. Isolation of plant MMR genes allows for the elucidation of primary amino acid structures as described in EXAMPLE 1. Peptides containing some but not all of the domains can be synthesized from domains of the particular MMR gene and introduced into host plants using methods known by those skilled in the art (22). Like truncated PMS134, such peptides will compete with functional full length proteins for binding and form enzymatically inactive MMR complexes. The data indicate that the domains which are C-terminal to the 134 position in human PMS2 are dispensable for binding and necessary for enzymatic activity. As shown herein, a similar domain structure is also found in plant PMS2. Seedlings exhibiting hypermutability will be useful to produce genetically diverse offspring for commercial and medical applications.

RNA blockade and Double Stranded Interference.

MMR subunits (MutS and MutL proteins) interact to form active MMR complexes. Peptides are able to specifically inhibit the binding of two proteins by competitive inhibition. Antisense oligonucleotides are synthesized against the cDNA sequence of plant MMR homologs identified in EXAMPLE 1 (20). Antisense molecules are then introduced into host plants using methods described in EXAMPLE 2 or through the bathing of seedlings or plantlets. Seedlings exhibiting hypermutability will be useful to produce genetically diverse offspring for commercial and medical applications.

Double stranded interference vectors are also useful for blocking expression/function of a plant MMR gene. The plant gene is expressed in both sense and antisense orientations from a transfection vector and the endogenous gene expression is suppressed by endogenous silencing processes (21).

Discussion

Plants contain MMR genes that code for MMR functional proteins. Expression of dominant negative plant MMR proteins results in an increase in microsatellite instability and hypermutability in plants. This activity is due to the inhibition of MMR biochemical activity in these hosts. The data provided within this application demonstrates the blockade of MMR in a plant to produce genetic changes that lead to the production of offspring or cells with new output traits. This method is applicable to generate crop plants with new output traits as well as plant cells exhibiting new biochemicals for commercial use.

References cited (each of which is expressly incorporated herein for all purposes)

1. Liu, B., Parsons, R., Papadopoulos, N., Nicolaides, N.C., Lynch, H.T., Watson, P., Jass, J.R., Dunlop, M., Wyllie, A., Peltomaki, P., de la Chapelle, A., Hamilton, S.R., Vogelstein, B., and Kinzler, K.W. 1996. Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients. *Nat. Med.* 2:169-174.
2. Bronner, C.E., Baker, S.M., Morrison, P.T., Warren, G., Smith, L.G., Lescoe, M.K., Kane, M., Earabino, C., Lipford, J., Lindblom, A., Tannergard, P., Bollag, R.J., Godwin, A., R., Ward, D.C., Nordenskjold, M., Fishel, R., Kolodner, R., and Liskay, R.M. 1994. Mutation in the DNA mismatch repair gene homologue *hMLH1* is associated with hereditary non-polyposis colon cancer. *Nature* 368:258-261.

3. Leach, F.S., Nicolaides, N.C., Papadopoulos, N., Liu, B., Jen, J., Parsons, R., Peltomaki, P., Sistonen, P., Aaltonen, L.A., Nystrom-Lahti, M., Guan, X.Y., Zhang, J., Meltzer, P.S., Yu, J.W., Kao, F.T., Chen, D.J., Cerosaletti, K.M., Fournier, R.E.K., Todd, S., Lewis, T., Leach R.J., Naylor, S.L., Weissenbach, J., Mecklin, J.P., Jarvinen, J.A., Petersen, G.M., Hamilton, S.R., Green, J., Jass, J., Watson, P., Lynch, H.T., Trent, J.M., de la Chapelle, A., Kinzler, K.W., and Vogelstein, B. 1993. Mutations of a *mutS* homolog in hereditary non-polyposis colorectal cancer. *Cell* 75:1215-1225.
4. Nicolaides, N.C., Papadopoulos, N., Liu, B., Wei, Y.F., Carter, K.C., Ruben, S.M., Rosen, C.A., Haseltine, W.A., Fleischmann, R.D., Fraser, C.M., Adams, M.D., Venter, C.J., Dunlop, M.G., Hamilton, S.R., Petersen, G.M., de la Chapelle, A., Vogelstein, B., and kinzler, K.W. 1994. Mutations of two PMS homologs in hereditary nonpolyposis colon cancer. *Nature* 371: 75-80.
5. Nicolaides, N.C., Palombo, F., Kinzler, K.W., Vogelstein, B., and Jiricny, J. 1996. Molecular cloning of the N-terminus of GTBP. *Genomics* 31:395-397.
6. Palombo, F., Gallinari, P., Iaccarino, I., Lettieri, T., Hughes, M.A., Truong, O., Hsuan, J.J., and Jiricny, J. 1995. GTBP, a 160-kilodalton protein essential for mismatch-binding activity in human cells. *Science* 268:1912-1914.
7. Papadopoulos, N., Nicolaides, N.C., Wei, Y.F., Carter, K.C., Ruben, S.M., Rosen, C.A., Haseltine, W.A., Fleischmann, R.D., Fraser, C.M., Adams, M.D., Venter, C.J., Dunlop, M.G., Hamilton, S.R., Petersen, G.M., de la Chapelle, A., Vogelstein, B., and kinzler,

- K.W. 1994. Mutation of a mutL homolog is associated with hereditary colon cancer. *Science* 263:1625-1629.
8. Perucho, M. 1996. Cancer of the microsatellite mutator phenotype. *Biol Chem.* 377:675-684.
9. Strand, M., Prolla, T.A., Liskay, R.M., and Petes, T.D. Destabilization of tracts of simple repetitive DNA in yeast by mutations affecting DNA mismatch repair. 1993. *Nature* 365:274-276.
10. Ma AH, Xia L, Littman SJ, Swinler S, Lader G, Polinkovsky A, Olechnowicz J, Kasturi L, Lutterbaugh J, Modrich P, Veigl ML, Markowitz SD, Sedwick WD. 2000. Somatic mutation of hPMS2 as a possible cause of sporadic human colon cancer with microsatellite instability. *Oncogene* 19:2249-2256.
- ~~11. Parsons, R., Li, G.-M., Longley, M.-J., Fang, W.-H., Papadopoulos, N.,~~
Jen, J., de la Chapelle, A., Kinzler, K.W., Vogelstein, B., and Modrich, P. 1993. Hypermutability and mismatch repair deficiency in RER⁺ tumor cells. *Cell* 75:1227-1236.
12. Li, G.-M., and Modrich, P. 1995. Restoration of mismatch repair to nuclear extracts of H6 colorectal tumor cells by a heterodimer of human mutL homologs. *Proc. Natl. Acad. Sci. USA* 92:1950-1954.
13. Nicolaides N.C. et.al. 1998. A naturally occurring hPMS2 mutation can confer a dominant negative mutator phenotype. *Mol Cell Biol.* 18:1635-1641.

14. Modrich, P. 1994. Mismatch repair, genetic stability, and cancer. *Science* 266:1959-1960.
15. Pang, Q., Prolla, T.A., and Liskay, R.M. 1997. Functional domains of the *Saccharomyces cerevisiae* Mlh1p and Pms1p DNA mismatch repair proteins and their relevance to human hereditary nonpolyposis colorectal cancer-associated mutations. *Mol. Cell. Biol.* 17:4465-4473.
16. Harfe, B.D., and Jinks-Robertson, S. 2000. DNA MISMATCH REPAIR AND GENETIC INSTABILITY. *Annu Rev Genet* 34:359-399.
17. Culligan, K.M, and Hays, J.B. 1997. DNA mismatch repair in plants. An *Arabidopsis thaliana* gene that predicts a protein belonging to the MSH2 subfamily of eukaryotic MutS homologs. *Plant Physiol.* 115:833-839.
18. Jean M, Pelletier J, Hilpert M, Belzile F, and Kunze R. 1999. mutl Plant Isolation and characterization of AtMLH1, a MutL homologue from *Arabidopsis thaliana*. *Mol Gen Genet.* 262:633-642.
19. de Wind N., Dekker, M., Berns, A., Radman, M., and Riele, H.T. 1995. Inactivation of the mouse *Msh2* gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer. *Cell* 82:321-300.
20. Hackett RM, Ho CW, Lin Z, Foote HC, Fray RG, Grierson D. 2000. Antisense inhibition of the Nr gene restores normal ripening to the tomato never-ripe mutant, consistent with the ethylene receptor-inhibition model. *Plant Physiol* 124:1079-1086.

21. Chuang CF, Meyerowitz EM. 2000. Specific and heritable genetic interference by double-stranded RNA in *Arabidopsis thaliana*. *Proc Natl Acad Sci U S A* 97:4985-4990.
22. Takeuchi M, Ueda T, Sato K, Abe H, Nagata T, and Nakano A. 2000. A dominant negative mutant of sar1 GTPase inhibits protein transport from the endoplasmic reticulum to the golgi apparatus in tobacco and *arabidopsis* cultured cells. *Plant J*. 23:517-525.
23. Nicolaides, N.C., Carter, K.C., Shell, B.K., Papadopoulos, N., Vogelstein, B., and Kinzler, K.W. 1995. Genomic organization of the human PMS2 gene family. *Genomics* 30:195-206.
24. Horii, A., et.al. 1994. Cloning, characterization and chromosomal assignment of the human genes homologous to yeast PMS1, a member of mismatch repair genes. *Biochem Biophys Res Commun*. 204:1257-1264.
25. Moffat, A.S., 1999. Engineering plants to cope with metals. *Science* 285:369-370.
26. Mazur, B., Krebbers, E., and Tingey, S. 1999. Gene discovery and product development for grain quality traits. *Science*. 285:372-375.
27. Shintani, D., and DellaPenna, D. 1998. Elevating the Vitamin E content of plants through metabolic engineering. *Science*. 282:2098-2100.

28. Peng, J., Richards, D.E., Hartley, N.M., Murphy, G.P., et.al. 1999. "Green revolution" genes encode for mutant gibberellin response modulators. *Nature*. 256-261.
29. DellaPenna, D. 1999. Nutritional genomics: Manipulating plant micronutrients to improve human health. *Science*. 285:375-379.
30. Nicolaides N.C., Kinzler, K.W., and Vogelstein, B. 1995. Analysis of the 5' region of PMS2 reveals heterogenous transcripts and a novel overlapping gene. *Genomics* 29:329-334.
31. Murai, N., Sutton, D.W., Murray, M.G., Slightom, J.L., Merlo, D.J., et.al. 1983. *Science*. 222:476-???
32. Koziel, M.G., Adams, T.L., Hazlet, M.A., et.al., 1984. *J. MOL. Appl. Genet.* 2:549-560.
33. Kaulen, H., Schell, J., and Kreuzaler, F. 1986. *EMBO J.* 5:1
34. Nicolaides, N.C., Correa, I., Casadevall, C., Travali, S., Soprano, K.J., and Calabretta, B. 1992. The Jun family members, c-JUN and JUND, transactivate the human *c-myc* promoter via an Apl like element. *J. Biol. Chem.* 267, 19665-19672.
35. Wheeler JM, Loukola A, Aaltonen LA, Mortensen NJ, and Bodmer WF. 2000. The role of hypermethylation of the hMLH1 promoter region in HNPCC versus MSI+ sporadic colorectal cancers. *J. Med. Genet.* 37:588-592.
36. Hoang JM, Cottu PH, Thuille B, Salmon RJ, Thomas G, and Hamelin R. 1997. BAT-26, an indicator of the replication error

phenotype in colorectal cancers and cell *lines*. *Cancer Res* 57:300-303.

37. Bell, C.J., et.al. *Genomics*, 19:137-144, 1994.

38. Gal, S., Pisan, B., Hohn, T., Grimsley, N., and Hohn, B. 1991.
Genomic homologous recombination in planta. *EMBO J.*
10:1571-1578.

WE CLAIM:

1. A method for making a hypermutable cell, comprising the step of:
introducing into a plant cell a polynucleotide comprising a dominant negative allele of a mismatch repair gene, whereby the cell becomes hypermutable.
2. The method of claim 1 wherein the polynucleotide is introduced by transfection of a suspension of plant cells *in vitro*.
3. The method of claim 1 wherein the mismatch repair gene is a plant *MutS* homolog.
4. The method of claim 1 wherein the mismatch repair gene is a plant *MutL* homolog.
5. The method of claim 1 wherein the mismatch repair gene is a mammalian *PMS2*.
6. The method of claim 1 wherein the mismatch repair gene is a mammalian *MLH1*.
7. The method of claim 1 wherein the mismatch repair gene is a mammalian *PMS1*.
8. The method of claim 1 wherein the mismatch repair gene is a mammalian *MSH2*.
9. The method of claim 1 wherein the mismatch repair gene is an eukaryotic *mutS*.
10. The method of claim 1 wherein the mismatch repair gene is an eukaryotic *mutL*.
11. The method of claim 1 wherein the mismatch repair gene is a prokaryotic *mutS*.
12. The method of claim 1 wherein the mismatch repair gene is a prokaryotic *mutL*.
13. The method of claim 3 wherein the allele comprises a truncation mutation.
14. The method of claim 4 where the allele comprises a truncation mutation.

15. The method of claim 5 where the allele comprises a truncation mutation.
16. The method of claim 15 wherein the allele comprises a truncation mutation at codon 134.
17. The method of claim 16 wherein the truncation mutation is a thymidine at nucleotide 424 of wild-type human *PMS2*.
18. The method of claim 1 wherein the polynucleotide is introduced into a plant cell in a plant to form a transgenic plant.
19. The method of claim 18 further comprising: growing the transgenic plant to form a mature transgenic plant.
20. The method of claim 19 wherein the mismatch repair gene is *PMS2*.
21. The method of claim 19 wherein the mismatch repair gene is a mammalian *PMS2*.
22. The method of claim 19 wherein the mismatch repair gene is a mammalian *MLH1*.
23. The method of claim 19 wherein the mismatch repair gene is a mammalian *PMS1*.
- ~~24. The method of claim 19 wherein the mismatch repair gene is a mammalian *MSH2*.~~
25. The method of claim 19 wherein the mismatch repair gene is a plant *MutS* homolog.
26. The method of claim 19 wherein the mismatch repair gene is a plant *MutL* homolog.
27. The method of claim 19 wherein the mismatch repair gene is an eukaryotic *MutS* homolog.
28. The method of claim 19 wherein the mismatch repair gene is an eukaryotic *MutL* homolog.
29. The method of claim 19 wherein the mismatch repair gene is a prokaryotic *MutS* homolog.
30. The method of claim 19 wherein the mismatch repair gene is a prokaryotic *MutL* homolog.

31. The method of claim 20 wherein the allele comprises a truncation mutation.
32. The method of claim 20 wherein the allele comprises a truncation mutation at codon 134.
33. The method of claim 20 wherein the truncation mutation is a thymidine at nucleotide 424 of wild-type *hPMS2*.
34. A homogeneous composition of cultured, hypermutable, plant cells which comprise a dominant negative allele of a mismatch repair gene.
35. The homogeneous composition of claim 34 wherein the mismatch repair gene is *PMS2*.
36. The homogeneous composition of claim 34 wherein the mismatch repair gene is mammalian *PMS2*.
37. The homogeneous composition of claim 34 wherein the mismatch repair gene is mammalian *MLH1*.
38. The homogeneous composition of claim 34 wherein the mismatch repair gene is mammalian *PMS1*.
39. The homogeneous composition of claim 34 wherein the mismatch repair gene is mammalian *MSH2*.
40. The homogeneous composition of claim 34 wherein the mismatch repair gene is a plant MutS homolog.
41. The homogeneous composition of claim 34 wherein the mismatch repair gene is a plant MutL homolog.
42. The homogeneous composition of claim 34 wherein the mismatch repair gene is an eukaryotic MutS homolog.
43. The homogeneous composition of claim 34 wherein the mismatch repair gene is an eukaryotic MutL homolog.
44. The homogeneous composition of claim 34 wherein the mismatch repair gene is a prokaryotic MutS homolog.
45. The homogeneous composition of claim 34 wherein the mismatch repair gene is a prokaryotic MutL homolog.

46. The homogeneous composition of claim 34 wherein the cells express a protein consisting of the first 133 amino acids of hPMS2.

47. A hypermutable transgenic plant wherein at least 50% of the cells of the plant comprise a dominant negative allele of a mismatch repair gene.

48. The hypermutable transgenic plant of claim 47 wherein the mismatch repair gene is a plant *MutS*.

49. The hypermutable transgenic plant of claim 47 wherein the mismatch repair gene is a plant *MutL*.

50. The hypermutable transgenic plant of claim 47 wherein the mismatch repair gene is a mammalian *MutS* homolog.

51. The hypermutable transgenic plant of claim 47 wherein the mismatch repair gene is a mammalian *MutL* homolog.

52. The hypermutable transgenic plant of claim 47 wherein the mismatch repair gene is an eukaryotic *MutS* homolog.

53. The hypermutable transgenic plant of claim 47 wherein the mismatch repair gene is an eukaryotic *MutL* homolog.

54. The hypermutable transgenic plant of claim 47 wherein the mismatch repair gene is a prokaryotic *MutS* homolog.

55. The hypermutable transgenic plant of claim 47 wherein the mismatch repair gene is a prokaryotic *MutL* homolog.

56. The hypermutable transgenic plant of claim 47 comprising a protein which consists of the first 133 amino acids of human *PMS2*.

57. A method for generating a mutation in a gene of interest in a plant cell, comprising the steps of:

growing a hypermutable plant cell comprising the gene of interest and a dominant negative allele of a mismatch repair gene;

testing the cell to determine whether the gene of interest harbors a mutation.

58. The method of claim 57 wherein the step of testing comprises analyzing a nucleotide sequence of the gene of interest.

59. The method of claim 57 wherein the step of testing comprises analyzing mRNA transcribed from the gene of interest.
60. The method of claim 57 wherein the step of testing comprises analyzing a protein encoded by the gene of interest.
61. The method of claim 57 wherein the step of testing comprises analyzing a phenotype caused by the gene of interest.
62. The method of claim 57 wherein the plant cell is made by the process of introducing a polynucleotide comprising a dominant negative allele of a mismatch repair gene into a plant cell, whereby the cell becomes hypermutable.
63. The method of claim 62 wherein the step of testing comprises analyzing a nucleotide sequence of the gene of interest.
64. The method of claim 62 wherein the step of testing comprises analyzing mRNA transcribed from the gene of interest.
65. The method of claim 62 wherein the step of testing comprises analyzing a protein encoded by the gene of interest.
66. The method of claim 62 wherein the step of testing comprises analyzing a phenotype caused by the gene of interest.
67. A method for generating a mutation in a gene of interest in a plant, comprising the steps of:
- growing a plant comprising the gene of interest and a polynucleotide encoding a dominant negative allele of a mismatch repair gene;
 - testing the plant to determine whether the gene of interest harbors a mutation.
68. The method of claim 67 wherein the step of testing comprises analyzing a nucleotide sequence of the gene of interest.
69. The method of claim 67 wherein the step of testing comprises analyzing mRNA transcribed from the gene of interest.
70. The method of claim 67 wherein the step of testing comprises analyzing a protein encoded by the gene of interest.

71. The method of claim 67 wherein the step of testing comprises analyzing a phenotype caused by the gene of interest.
72. The method of claim 67 wherein the plant is made by the process of introducing a polynucleotide comprising a dominant negative allele of a mismatch repair gene into a plant, whereby the plant becomes hypermutable.
73. The method of claim 72 wherein the step of testing comprises analyzing a nucleotide sequence of the gene of interest.
74. The method of claim 72 wherein the step of testing comprises analyzing mRNA transcribed from the gene of interest.
75. The method of claim 72 wherein the step of testing comprises analyzing a protein encoded by the gene of interest.
76. The method of claim 72 wherein the step of testing comprises analyzing the phenotype of the gene of interest.
77. A hypermutable transgenic plant made by the method of claim 67.
78. The hypermutable transgenic plant of claim 77 wherein the mismatch repair gene is *PMS2*.
79. The hypermutable transgenic plant of claim 77 wherein the mismatch repair gene is human *PMS2*.
80. The hypermutable transgenic plant of claim 77 wherein the mismatch repair gene is human *MLH1*.
81. The hypermutable transgenic plant of claim 77 wherein the mismatch repair gene is human *PMS1*.
82. The hypermutable transgenic plant of claim 77 wherein the mismatch repair gene is human *MSH2*.
83. The hypermutable transgenic plant of claim 77 wherein the allele comprises a truncation mutation.
84. The hypermutable transgenic plant of claim 77 wherein the allele comprises a truncation mutation at codon 134.
85. The hypermutable transgenic plant of claim 83 wherein the truncation mutation is a thymidine at nucleotide 424 of wild-type *PMS2*.
86. A method for generating a hypermutable plant, comprising the steps of:

inhibiting endogenous mismatch repair (MMR) activity of a plant, whereby the plant becomes hypermutable.

87. The method of claim 86 wherein an endogenous plant MutS homolog is inhibited by mutagenizing an allele encoding the MutS homolog by introducing a mutation into said allele by homologous recombination.

88. The method of claim 86 wherein an endogenous plant MutL homolog is inhibited by mutagenizing an allele encoding the MutL homolog by introducing a mutation into said allele by homologous recombination.

89. The method of claim 86 wherein an endogenous plant MutL homolog is inhibited by introduction of a dominant negative allele of a plant MutL gene.

90. The method of claim 86 wherein an endogenous plant MutS homolog is inhibited by introduction of a dominant negative allele of a plant MutS gene.

91. The method of claim 86 wherein endogenous MMR activity is inhibited by introducing into said plant inhibitory peptides derived from plant MutS proteins.

92. The method of claim 86 wherein endogenous MMR activity is inhibited by introducing into said plant inhibitory peptides derived from plant MutL proteins.

93. The method of claim 86 wherein endogenous MMR activity is inhibited by introducing into said plant antisense *MutS* oligodeoxynucleotides.

94. The method of claim 86 wherein endogenous MMR activity is inhibited by introducing into said plant antisense *MutL* oligodeoxynucleotides.

95. The method of claim 86 wherein endogenous MMR activity is inhibited by introducing a polynucleotide encoding a MutS polypeptide from a lower organism into said plant and overexpressing in said plant the MutS polypeptide from the lower organism.

96. The method of claim 86 wherein wherein endogenous MMR activity is inhibited by introducing a polynucleotide encoding a MutL polypeptide from a lower organism into said plant and overexpressing in said plant the MutL polypeptide from the lower organism.

97. The method of claim 95 wherein the lower organism is a bacterium.

98. The method of claim 95 wherein the lower organism is a yeast.

99. The method of claim 95 wherein the lower organism is a unicellular organism.

100. The method of claim 96 wherein the lower organism is a bacterium.

101. The method of claim 96 wherein the lower organism is a yeast.

102. The method of claim 96 wherein the lower organism is a unicellular organism.

103. The method of claim 86 wherein endogenous MMR activity is inhibited by introducing a polynucleotide encoding a MutL polypeptide from a rodent into said plant and overexpressing in said plant the MutL polypeptide from the rodent.

104. The method of claim 86 wherein endogenous MMR activity is inhibited by introducing a polynucleotide encoding a MutS polypeptide from a rodent into said plant and overexpressing in said plant the MutS polypeptide from the rodent.

105. The method of claim 86 wherein endogenous MMR activity is inhibited by double stranded RNA interference of endogenous plant MMR.

106. A vector for introducing a dominant negative MMR allele into a plant, comprising: a dominant negative MMR allele under the transcriptional control of a promoter which is functional in a plant.

107. The vector of claim 106 wherein said vector further comprises an *Agrobacterium tumefaciens* T-DNA border repeat flanking the MMR allele.

108. The vector of claim 106 further comprising an origin of replication for independent replication in said plant.

109. The vector of claim 106 wherein the promoter is a Cauliflower Mosaic Virus promoter.

110. The vector of claim 106 wherein the promoter is a nopaline synthase promoter from *Agrobacterium tumefaciens*.

111. The vector of claim 106 further comprising a selectable marker.

112. The vector of claim 111 wherein the selectable marker is a neomycin phosphotransferase gene.

113. The vector of claim 106 wherein the MMR allele is PMS134.

114. The vector of claim 106 wherein the MMR allele is human PMS134.

115. The vector of claim 106 wherein the MMR allele is Arabidopsis PMS134.

116. An isolated and purified polynucleotide encoding Arabidopsis PMS2 as shown in SEQ ID NO: 14.


117. The isolated and purified polynucleotide of claim 116 comprising the sequence as shown in SEQ ID NO: 4.
118. An isolated and purified polynucleotide encoding Arabidopsis PMS134 as shown in SEQ ID NO: 16.
119. The isolated and purified polynucleotide of claim 118 comprising the sequence as shown in SEQ ID NO: 6.
120. An isolated and purified protein which is Arabidopsis PMS2 as shown in SEQ ID NO: 14.
121. An isolated and purified protein which is Arabidopsis PMS134 as shown in SEQ ID NO: 16.
122. A method for determining the presence of a mismatch repair (MMR) defect in a plant or a plant cell, comprising:
 - comparing at least two microsatellite markers in test cells or a test plant to the at least two microsatellite markers in cells of a normal plant;
 - identifying the test cells or test plant as having a mismatch repair defect if at least two microsatellite markers are found to be rearranged relative to the cells of the normal plant.
123. The method of claim 122 wherein a test plant is identified if at least one quarter of the markers compared are found to be rearranged.
124. The method of claim 122 wherein a test plant is identified if at least one third of the markers compared are found to be rearranged.
125. The method of claim 122 wherein a test plant is identified if at least one half of the markers compared are found to be rearranged.

```

      2661                                     2730
humPMS2 (2574) A T T G AC-----
AtPMS2 (2267) T T A T T C T TACCTGATGACGACAATGTCAATGATGATGATGATGATGATGCAACCATCTCATTGGC
Consensus (2661) C TT CTCA A
      2731
humPMS2 (2587) ----
AtPMS2 (2337) ATGA
Consensus (2731)

```

Figure 1. Alignment between human PMS2 (humPMS134) and Arabidopsis thaliana homologue of PMS2 (AtPMS2) DNA sequences. Similarity is 48.1%; identity is 48.1%. Black boxes show identical nucleotides.



humPMS2	(1)	-----[RA]SS-----EPAKAKPIDRKS[HC]CS[Q]VLSLST[AKK]N[AKK]GATN[DL]	70
AtMLH1	(1)	MIDSSSLTAE[EE]E[PA]TIVPREPPK[OR]LEESV[NR]AA[E]IQRVPS[AVN]V[AKK]DSSS[SV]	
Consensus	(1)	ME ES AT I ID V I AG VI SAVKELVENSIDA AS I L	
humPMS2	(57)	KL[AY]VD[EE]E[AN]C[VEE]NFEG[TLK]H[AKK]IOE[AA]TQVET[FP]RA[AS]LCA[SD]IS[CH]	140
AtMLH1	(71)	VV[AG]LK[Q]Q[ND]H[IR]R[DL]PI[CER]T[ET]LTKE[EF]SLSSM[EE]E[AA]MTYVAH[VT]IT	
Consensus	(71)	LKD GL LI VSD G GI E L KH TSKI F DL L S GFRGEALASL LA VTIST	
humPMS2	(127)	ASAKV[IT]LMFDHNGKIIQKTPYPRPR[TVS]Q[Q]ESTLPV[H]EF[RI]IKKE[AA]M[QV]HAYC[ISA]	210
AtMLH1	(141)	KGQIH[Y]VSYRDGVMEHEPKACA[AVK]Q[Q]IM[EN]YNMIA[R]TL[Q]SADD[GI]DL[SR]MA[HYN]	
Consensus	(141)	G RL F KGT I V NLF L R K Q N DYAKIV LL I	
humPMS2	(197)	GIRV[IT]NQLGQ[AKRPV]CTGG[EE]IKEN[GE]F[OK]QLOS[IPFV]QLPPSDSVCEEYGL[CS]ALHNL	280
AtMLH1	(210)	NVSF[IR]KH[AVKAD]HSVV[IR]LDS[R]EY[VS]VAKN[M]KV[EE]V[SC]SSGCT	
Consensus	(211)	I SC G V S SPS D I SVFG LI L LS DA	
humPMS2	(267)	[YIS]E[IT]QCTHGVRSSSTDROFF[ER]PCDPAKVC[LVNE]HM[YNR]HQQ[EV]LNM[SVDS]C[CH]	350
AtMLH1	(264)	DME[ET]NSNYVAKKTI[VL]T[ED]LVECSALK[AI]EI[AA]TLPKASK[EV]YMS[IN]LPR[HET]	
Consensus	(281)	F I GFISN H KS FIN R D A L R I VY K PFV L I L E VDI	
humPMS2	(336)	VT[D]RQIL[QEEK]LLAVLKTSLIGMFDSDVNKLNV[QOPL]LDVEGNLI[MHA]DLEKPMV[KQDQ]SPS	420
AtMLH1	(331)	IH[ET]KEVS[INQEI]IEMIQ[VE]E[VE]V[LRN]NDTRTFQ[OKVEY]IQ	
Consensus	(351)	I P KK I L III MI S IKL A K E	
humPMS2	(406)	LRTGEE[KVSI]RLREAFSLRHT[ENK]HSPKTPPEPRS[L]OKRGM[SSST]SGAISDKGV[RPQKEA]	490
AtMLH1	(377)	STLTQS[IS]SPV[OKPSG]---[OK]QKV[VNK]MVRTDSSD[ARLHAF]QPKQSLPDKVSS[SVVRSS]	
Consensus	(421)	K D IS A T P P G A L L K AV	
humPMS2	(476)	SSSHG[SDPT]RAE[EKDS]GHGSTSVDSEGFSPDTGSHCSSEYAA[SGDR]SC[RR]DSQEKAPET[S]	560
AtMLH1	(443)	RQRRN[KETA]LSS[QE]-----LIA--G-----V-D[CCHP]ML[ET]RNCTYVGM[AV]	
Consensus	(491)	P D D A V I S G E V DD	
humPMS2	(546)	SD[DCHS]NQED[GCKFRV]LPQPTNLATPNT[RFKKEE]I[SSSD]ICQKLVNTQDMSA[QVDVAVK]INKKV	630
AtMLH1	(489)	AL[QYN]-----HLYLAN[---]VVNLS[ELMYQOT]RRFAHFNAIQLSDPAPL[ELILAL]KEEDL	
Consensus	(561)	FA V T SK L N I S S L L L	
humPMS2	(616)	V[LDFS]MSS[AKK]QLHH[AQOSEG]QNYRK[RAK]CPGE[QAAE]DEL[KEISK]T[FAEM]IIGQFN[AK]	700
AtMLH1	(547)	D[GNDTKDD]KE[EAEMNT]LLKEKA[MLEEY]SVH[DSSA]LSRLPVILDQYTPD[DRVP]FL[LC]	
Consensus	(631)	P S L RI L E AE F I N A I S M E I LG	
humPMS2	(686)	FIITKLN[DIFIVDQH]TDEKYNFEMLQOHTVLO[ORLIAPQ]TLNLTAVNEAV[IE]LEIFRKNGE[FEVI]	770
AtMLH1	(615)	NDVEWED[KSCFQGV]S[AIGNFYAMHP]LLPNPS[DG]IQFYSKRGESSQEKSD[EG]VDMEDNLD[LLS]	
Consensus	(701)	I E A F G I SA A L NLDI D L	
humPMS2	(756)	ENAPVTE[AKLIS]LPTSKNT[TFGPQD]VDELIFM[SDSPGV]MCRPSR[QMFASR]ACRKSVMIGTALNTS	840
AtMLH1	(685)	EAENAWAQ[---]E[SIQHV]LFP[SMRLF]KPPASMASNGTF[VASLEK]LYKIFERC[---]	
Consensus	(771)	D R WS L L M S VK K K	
humPMS2	(826)	EMKKLITHMGEMDHPWNC[PHGRPT]MRHIANLGVISON	877
AtMLH1	(738)	-----	
Consensus	(841)	-----	

Figure 3. Alignment between human PMS2 (humPMS2) and Arabidopsis thaliana PMS2 homologue MLH1 (AtMLH1) amino acid sequences. Similarity is 30%; identity is 18.4%. Black boxes show identical residues.

humPMS2	(1)	MERAESSSTEPA	1	70
AtPMS1	(1)	MTTLPPEGVR		
Consensus	(1)	K IKPI H I SG IM LA V ELV NSLDAGAT I I L I V D		
humPMS2	(71)	N C E E E N F E G T L K H H I Q E A D L Q V L S L S T A K E D A A A N I D L K L K D Y G V D L I E S	71	140
AtPMS1	(59)	D S S R R D D L V L G E R Y A F H D T N V E A S T P G E G G A A I S D I L L E V R K A I G R P N Y K V M K G		
Consensus	(71)	G G V D L K H T S K D F L T E T F G F R G E A L A S I I S L I T G R M		
humPMS2	(140)	NGKIIQKTPYP P R I S Q O Q S T L E H E F R N I E Y A K M V Q V L H A Y C I I S A G I	141	210
AtPMS1	(129)	SKCLHLGIDDD K D S H T R D Y S Q V R Y M S S P V L E S I K K C V F R I A L V H S N V S F S V L D I E S D		
Consensus	(141)	I R G T T V S V L F S P V R K Q K K I L I I A I		
humPMS2	(199)	-----R C T N O L G O G R Q P V V C G S P S I K E I I S V	211	280
AtPMS1	(199)	E E L F Q T N P S S A F S L L M R D A G T E A V N S L C K V N V T D G M L N G F E C A D D W P T D G Q C R R N R L Q S F Y I		
Consensus	(211)	VS K T G I N G I		
humPMS2	(231)	-----G Q K Q L Q S L I P V O L P I S D S V C E Y G S C S D A L H N F Y I S F I S Q C T H V G R S S T R Q F	281	350
AtPMS1	(269)	L C I A C P R R L Y E S F E P S K T H V E K K W C V L A F I R I T A N W K D R I E L F D G A D I L A K D R Q D L I D K I		
Consensus	(281)	F S I F P A E L A L G G D		
humPMS2	(290)	FFI R -----R P C D V C R L V N E V Y H M Y N R H O Y F V V L N I S V S E C V D I N T P D K R Q I L	351	420
AtPMS1	(339)	R L G S S L F S I L H F L D A D W P E A M E K K L K R S N D H A P C S S L L F S A D F K Q D C Y F S P R K D W S P E C E V E		
Consensus	(351)	N D P A K H F P D V I L		
humPMS2	(346)	Q E E K L L L A V L K T S L I G M F D V N K L N V S C P L L V E G N L I K M H A A D L E K P M V E D Q S P S L R G E E K K D V	421	490
AtPMS1	(409)	K I O N P K E Q G T V A G F E S R T L L Q S R D I E M T N E F P Q V T D L L E T S L V A D S K C R F L T R C Q I T P V N I N H		
Consensus	(421)	D S L N I Q D L A L K Q S T		
humPMS2	(416)	S I S R L R E A F S -----R T T E N K P H S K T E P R R P L G Q	491	560
AtPMS1	(479)	D F M K D S D V L N F Q F Q L K D E L D V S N C I G K H L L R G C S S R V S L T F H E P K S V E G Y E S V V M I N E K Q S P R V		
Consensus	(491)	K D L H P P K S		
humPMS2	(450)	K R G M L S S T S G A I G V L R P Q K E A V S S S H G -----S D P T A E E K D S G H G S S V S E G S I P T G S H C S S	561	630
AtPMS1	(549)	L E T R E G G Y C D V Y H T P D C S L G S S W Q D T D W F T O C S S G C G I G E D F N I P I T A E D S Y E K V G S K K		
Consensus	(561)	S S D K A S P S D R A V T I D S F D		
humPMS2	(518)	E Y A A S S P D R G S Q E H V D Q -----K A E T D D S F D V D C H S N Q E D T G C K F R V L C T N L A T P N T K R F K F E	631	700
AtPMS1	(619)	Y L S S V N V S S V T G S F C L S W S P M Y S T S A T K W E Y E Q K G R I L E Q S L R L G R M D E F C F S A A N N I K F D H		
Consensus	(631)	A A G S S E P S D D K L P P S		
humPMS2	(583)	I L S S S I I O K L V N T Q D M S A S Q V D V V N N K -----V V P L O F S M S L A I R I K Q L H H E A Q S E E P N Y R K F	701	770
AtPMS1	(689)	I V I P E M C E T G T D S F T A I O N C T O L D E C S S W G H A D D V R I D Q Y I R E K F S Y M D G T N N A K R S K R S		
Consensus	(701)	E I I D C S L A K I K L S I K Q N G Q K K		
humPMS2	(649)	PAKICPGENQ-----	771	840
AtPMS1	(759)	S A P F Y R E K K R F I S L S C K S D T K P K N S D P S E P D D L E C L T Q P C N A S Q M H L K C S I L D D V S Y D H I Q E T E K R L S		
Consensus	(771)	R A		
humPMS2	(659)	-----	841	910
AtPMS1	(829)	S A S D L K A S A G C R T V H S E T Q D E D V H E D F S S E E F L D P I K S T T K W R H N C A V S Q V P K E S H E L H G Q D G V F D I S S G		
Consensus	(841)			
humPMS2	(659)	-----A A D E L R K E S K T M F A E M E I I G F N L G F I T K L N E D I F P H H T K Y N F M Q Q H T V L Q G Q R L	911	980
AtPMS1	(899)	L L H L R S D S L V P E S N R H S L E D A K V L Q V D K K Y P I V A C G T V A D K H A A R I R L E R T K F I N D A L L I		
Consensus	(911)	A E L I K D I I Q F I I I V D Q H A D E K E L I A I		
humPMS2	(724)	I A P Q T L N T A V N E A V I E N L I F K N F D F V D E N A P V T E R A K -----I S L T S K N W T F G P Q	981	1050
AtPMS1	(969)	F V L T L K V P E M G Y Q L Q S Y S Q I D W W I C N T V E G S T S F K K N M S I I Q R K P T P I T N A V C I L G V N L S D V		
Consensus	(981)	L M L L E R G F I A S K L A L P		
humPMS2	(782)	V D L I F M S S P V M C R S R K Q M F A R V E K S V I T A N T E M K K I T H M G E M D H P W N P R P F M R	1051	1120
AtPMS1	(1039)	L L F L O O A T D S S T I P S L R V L N K T T G A I F D S L F P C S L I D G L Q T S L C F C A A R P R T V		
Consensus	(1051)	D L E I L A D S G P V M S K A C R A I M G A L S E I I L F N C H G R P T		
humPMS2	(852)	H I A N G V I S Q N -----	1121	1164
AtPMS1	(1109)	P L V D K A L H K Q I A K L S G R Q V W H G L Q R R E I T L D R A K S R L D N A K S -		
Consensus	(1121)	I L I N		

Figure 4. Alignment between human PMS2 (humPMS2) and Arabidopsis thaliana PMS2 homologue PMS1 (AtPMS1) amino acid sequences. Similarity is 24.4%; identity is 15%. Black boxes show identical residues.




Figure 5. Phylogenetic tree of the *Arabidopsis thaliana* PMS2 gene homologues.

```

1                               70
humPMS134 (1) ATG GGC GAGAGCT GAG AAGAAG GAGG C----- GCA AATATG TCG AGT
AtPMS134 (1) ATG GAG GAA TCTTCTC TCC GACGAA GAGGCT TCCTTTG GAG GATTA CA AAGCG
Consensus (1) ATG A GAG T CG T C CT CTA C AT A ACCTAT A G AA
71                               140
humPMS134 (65) C G C TCAG T T C T T G G G G G A C GAGT AAGCA T T C A A A A T A A A A
AtPMS134 (71) T A T T CAG A C C T T C T T A A C A C T A G A C T C T T T G C C C A G A C T T C T A G
Consensus (71) A T CA AT TG TC GG CA GT T T CT C GC GT AAGGAG T GT GA AA
141                               210
humPMS134 (135) C G C G T T T T C A T A A T T C A G T A A G T A A G T A A G A A T
AtPMS134 (141) T G T C C C C C C C C C G A A A G A T T C C C G A A A A A A A A A A A A
Consensus (141) A G T C T G A G C G G C C C A A T A T G A T A A C T G A C T A G G G A T T T A G T
211                               280
humPMS134 (205) T C A A A A A A A A A A G G ----- G A A G A ----- A A A T A A A G T A A
AtPMS134 (211) A T T A A A A A T T T T C A T T C C C C A A C C A T T C A G T T T G T G T C C A A T T C G A A A T T T G
Consensus (211) G A C A A T G G T G G T T C C C C A A C A A A A G A A C T C G A A G C T T
281                               350
humPMS134 (251) ----- T G A A A A C A A A A A G A T C A A G T G C C A A C C G G T A A A A
AtPMS134 (281) A T G T T C T T G A T T G T A T C A T T T T A A A T A G G T T C A A A T T T G A T T G A C T T T
Consensus (281) C C T A A C A T C A A C T C T A A T A G A T T C G A C T T A T T G A A C T T
351                               420
humPMS134 (311) T A A C T C G G G G G T C G G G A A T T T T G C A A C G G G A C A T T C T C T T C C
AtPMS134 (350) A G G T T A A A A A A A A G C T G A G C T T C G T G G T T G A A A C A A T G G G A A A A A A A
Consensus (351) T G G T T T G G G A A G C T G A G C T C T T G T G C A T G A T C A C T A C G C A
421                               444
humPMS134 (379) C C C G G G A G T T G A T ---
AtPMS134 (420) A A G A C C --- T T T C T G C T C
Consensus (421) G A T G C A G T T G A C

```


Figure 6. Alignment between human PMS134 (humPMS134) and Arabidopsis thaliana homologue of PMS134 (AtPMS134) DNA sequences. Similarity is 53.2%; identity is 53.2%. Black boxes show identical nucleotides.

```

1                               70
humPMS134 (1) --MERAEISSLEPAKAKKIDKSVQCTTCTVVSITVPAKPHLIRWINDLKKEVLLIE
AtPMS134 (1) MQGDSSPPTTSSPLRNNVIRKQRYIIDSTVHLVENVHIAWASLEINRVEYFO
Consensus (1) D A S S T A IKPI R IH ICSGQVIL LSSAVKELVENS LDAGAT IDI LKDYG D V
71                               140
humPMS134 (69) SNGPSVEEE-----EGTIRHILIOEATQVEFPPKDALMELCA SDVVISCHA
AtPMS134 (71) IHTTISPTKVCVQLRRTFDVAHHHSLEDTELNLTYPPKDALMELCA GNLVE RTK
Consensus (71) DNGCGI NF D L LKHHTSKI DF DL NL TFGFRGEALSSLCAL LTI T
141
humPMS134 (128) SAKGG
AtPMS134 (141) NEPA
Consensus (141) VAT

```

Figure 7. Alignment between human PMS134 (humPMS134) and Arabidopsis thaliana homologue of PMS134 (AtPMS134) amino acid sequences. Similarity is 65.1%; identity is 50.7%. Black boxes show identical residues.






Figure 9. Expression of the *Arabidopsis thaliana* PMS134 gene produces hypermutability in bacteria leading to the generation of new phenotypes. Briefly, bacteria containing the empty vector or the TAC ATPMS134 expression vector were grown and plated on kanamycin containing Lbagar plates. The host bacteria are susceptible to KAN bactericidal activity. Bacterial cultures expressing the hPMS134 gene resulted in genetic alteration of the bacterial host and the generation of clones that are KAN resistant.



Figure 10. Schematic map of the pCMV-hPMS134-Kan binary plant expression vector. Ag7 T. and NOS T. = gene 7 and Nopaline Synthase poly(A) signals, respectively. NOS Prom and CaMV Prom = Nopaline Synthase and Cauliflower Mosaic Virus promoters, respectively. L and R = left and right T-DNA border repeats, respectively. Arrows indicate direction of transcription.




Figure 11. Expression of hPMS134 in *Arabidopsis Thailana*. Message analysis for T1 plants shows steady state expression of dominant negative MMR genes in PMS134-Kan plants (A) while none is observed in control plants (B). Tubulin was used as an internal control to monitor sample loading and integrity.





Figure 13. The plant on the left is a wild type *A. thaliana* and the one on the right is MMR defective. Seeds from the MMR defective plant have been obtained and offspring have the same "double-meristem" trait.



SEQUENCE LISTING

<110> Nicolaides, Nicholas
Grasso, Luigi
Sass, Philip
Kinzler, Kenneth
Vogelstein, Bert

<120> A method for generating hypermutable
plants

<130> 01107.00069

<150> 60/183,333

<151> 2000-02-18

<160> 15

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 17

<212> DNA

<213> Human sapiens

<400> 1

atgcaaggag attcttc

17

<210> 2

<211> 21

<212> DNA

<213> Human sapiens

<400> 2

tcatgccaat gagatgggtg c

21

<210> 3

<211> 2589

<212> DNA

<213> Human sapiens

<400> 3

atggagcgag	ctgagagctc	gagtacagaa	cctgctaagg	ccatcaaacc	tattgatcgg	60
aagtcagtc	atcagatttg	ctctgggcag	gtggtactga	gtctaagcac	tgcggtaaag	120
gagttagtag	aaaacagctc	ggatgctggg	gccactaata	ttgatctaaa	gcttaaggac	180
tatggagtgg	atcttattga	agtttcagac	aatggatgtg	gggtagaaga	agaaaacttc	240
gaaggcttaa	ctctgaaaca	tcacacatct	aagattcaag	agtttgccga	cctaactcag	300
gttgaaactt	ttggctttcg	gggggaagct	ctgagctcac	tttgtgcact	gagcgatgtc	360
accatttcta	cctgccacgc	atcggcgaag	gttggaactc	gactgatgtt	tgatcacaat	420
gggaaaatta	tcagaaaaac	cccctacccc	cgccccagag	ggaccacagt	cagcgtgcag	480
cagttatttt	ccacactacc	tgtgcgccat	aaggaatttc	aaaggaatat	taagaaggag	540
tatgccaaaa	tgggccaggt	cttacatgca	tactgtatca	tttcagcagg	catccgtgta	600
agttgcacca	atcagcttgg	acaaggaaaa	cgacagcctg	tggtatgcac	aggtggaagc	660
cccagcataa	aggaaaatat	cggctctgtg	tttgggcaga	agcagttgca	aagcctcatt	720
ccctttgttc	agctgcccc	tagtgactcc	gtgtgtgaag	agtacggttt	gagctgttcg	780
gatgctctgc	ataatctttt	ttacatctca	ggtttcattt	cacaatgcac	gcatggagtt	840
ggaaggagtt	caacagacag	acagtttttc	tttatcaacc	ggcggccttg	tgaccagca	900
aaggctctga	gactcgtgaa	tgaggtctac	cacatgtata	atcgacacca	gtatccattt	960
gttggtctta	acattttctg	tgattcagaa	tgcgttgata	tcaatgttac	tccagataaa	1020
aggcaaat	tgctacaaga	ggaaaagctt	ttgttggcag	ttttaaaagac	ctctttgata	1080

ggaatgtttg	atagtgtatg	caacaagcta	aatgtcagtc	agcagccact	gctggatggt	1140
gaaggtaact	taataaaaaat	gcatgcagcg	gatttggaaa	agccccatggt	agaaaagcag	1200
gatcaatccc	cttcattaag	gactggagaa	gaaaaaaaag	acgtgtccat	ttccagactg	1260
cgagaggcct	tttctcttcg	tcacacaaca	gagaacaagc	ctcacagccc	aaagactcca	1320
gaaccaagaa	ggagccctct	aggacagaaa	aggggtatgc	tgtcttctag	cacttcaggt	1380
gccatctctg	acaaaggcgt	cctgagacct	cagaaagagg	cagtgaagt	cagtcacgga	1440
cccagtgacc	ctacgggacag	agcggagggtg	gagaaggact	cggggcacgg	cagcacttcc	1500
gtggattctg	aggggttcag	catcccagac	acgggcagtc	actgcagcag	cgagtatgcg	1560
gccagctccc	caggggacag	gggctcgag	gaacatgtgg	actctcagga	gaaagcgct	1620
gaaactgacg	actctttttc	agatgtggac	tgccattcaa	accaggaaga	taccggatgt	1680
aaatttcgag	ttttgcctca	gccaaactaat	ctcgcaaccc	caaacacaaa	gcgttttaaa	1740
aaagaagaaa	ttctttccag	ttctgacatt	tgctaaaagt	tagtaaatat	tcaggacatg	1800
tcagcctctc	aggttgatgt	agctgtgaaa	attaataaga	aagttgtgcc	cctggacttt	1860
tctatgagtt	cttttagctaa	acgaataaag	cagttacatc	atgaagcaca	gcaaagtga	1920
ggggaacaga	attacaggaa	gttttagggca	aagatttgtc	ctggagaaaa	tcaagcagcc	1980
gaagatgaac	taagaaaaga	gataagttaa	acgatgtttg	cagaaatgga	aatcattggt	2040
cagtttaacc	tgggatttat	aataaccaaa	ctgaatgagg	atatcttcat	agtggaccag	2100
catgccacgg	acgagaagta	taacttcgag	atgctgcagc	agcacaccgt	gctccagggg	2160
cagaggctca	tagcacctca	gactctcaac	ttaactgctg	ttaatgaagc	tgttctgata	2220
gaaaaatctg	aaatatattag	aaagaatggc	tttgattttg	ttatcgatga	aaatgctcca	2280
gtcactgaaa	gggctaaact	gatttccctg	ccaactagta	aaaactggac	cttcggaccc	2340
caggacgtcg	atgaactgat	cttcatgctg	agcgacagcc	ctgggggtcat	gtgccggcct	2400
tcccagagtca	acgagatggt	tgccctcaga	gcctgccgga	agtcggtgat	gattgggact	2460
gctcttaaca	caagcgagat	gaagaaactg	atcacccaca	tgggggagat	ggaccacccc	2520
tggaaactgtc	cccatggaag	gccaaacctg	agacacatcg	ccaacctggg	tgtcatttct	2580
cagaactag						2589

<210> 4

<211> 2340

<212> DNA

<213> Arabidopsis thaliana

<400> 4

atgcaaggag	attcttctcc	gtctccgacg	actactagct	ctcctttgat	aagacctata	60
aacagaaaag	taattcacag	aatctgttcc	ggteaagtea	tcttagaact	ctcttctggcc	120
gtcaaggagc	ttgtcgagaa	tagtctcgac	gccggcgcca	ccagtataga	gattaacctc	180
cgagactacg	gcgaagacta	ttttcaggta	attgacaatg	gttgtggcat	ttccccaaac	240
aatttcaagg	tttgtgtcca	aattctccga	agaacttttg	atgttcttgc	acttaagcat	300
catacttcta	aattagagga	tttcacagat	cttttgaatt	tgactactta	tggtttttaga	360
ggagaagcct	tgagctctct	ctgtgcattg	ggaaatctca	ctgtggaaac	aagaacaaaag	420
aatgagccag	ttgtactcgt	cttgacgttt	gatcattctg	gtttgcttac	tgctgaaaag	480
aagactgctc	gccaaattgg	taccactgtc	actgttagga	agttgttctc	taatttacct	540
gtacgaagca	aagagttaa	gcggaatata	cgcaaagaat	atgggaagct	tgtatcttta	600
ttgaacgcac	atgcgcttat	tgcgaaagga	gtgcggtttg	tctgctctaa	cacgactggg	660
aaaaacccaa	agtcgttgt	gctgaacaca	caagggaggg	gttcacttaa	agataatatc	720
ataacagttt	tcggcattag	tacctttaca	agtctacagc	ctggtagctg	acgcaattta	780
gcagatcgac	agtatttctt	tataaatggg	cggcctgtag	atatgccaaa	agtcagcaag	840
ttggtgaatg	agttatataa	agatacaagt	tctcggaat	atccagttac	cattctggat	900
tttattgtgc	ctggtggagc	atgtgatttg	aatgtcacgc	ccgataaaaag	aaagggtgtc	960
ttttctgacg	agacttctgt	tatcggttct	ttgagggaag	gtctgaacga	gatataattcc	1020
tccagtaatg	cgtcttatat	tgttaatagg	ttcgaggaga	attcggagca	accagataag	1080
gctggagttt	cgtcgtttca	gaagaaatca	aatcttttgt	cagaagggat	agttctggat	1140
gtcagttcta	aaacaagact	aggggaagct	attgagaaag	aaaatccatc	cttaaggggag	1200
gttgaaattg	ataatagttc	gccaatggag	aagtttaagt	ttgagatcaa	ggcatgtggg	1260
acgaagaaa	gggaagggtc	tttatcagtc	catgatgtaa	ctcaccttga	caagacacct	1320
agcaaagggt	tgccctgact	aaatgtgact	gagaaagtta	ctgatgcaag	taaaagactg	1380
agcagccgct	ctagctttgc	ccagtcaact	ttgaataact	ttgttaccat	gggaaaaaga	1440
aaacatgaaa	acataagcac	catcctctct	gaaacacctg	tcctcagaaa	ccaaacttct	1500
agttatcgtg	tggagaaaag	caaatttgaa	tctcgtgcct	tagcttcaag	gtgtctcgtg	1560
gaaggcgatc	aacttgatga	tatggctatc	tcaaagggaag	atatgacacc	aagcgaaaga	1620
gattctgaac	taggcaatcg	gatttctcct	ggaacacaa	ctgataatgt	tgaaagacat	1680
gagagagtac	tcgggcaatt	caatcttggg	ttcatcattg	caaaattgga	gcgagatctg	1740
ttcattgtgg	atcagcatgc	agctgatgag	aaattcaact	tcgaacattt	agcaagggtca	1800

actgtcctga	accagcaacc	cttactccag	cctttgaact	tggaactctc	tccagaagaa	1860
gaagtaactg	tgtaaatgca	catggatatt	atcagggaaa	atggctttct	tctagaggag	1920
aatccaagtg	ctctcccgg	aaaacacttt	agactacgag	ccattcctta	tagcaagaat	1980
atcacctttg	gagtcgaaga	tcttaaagac	ctgatctcaa	ctctaggaga	taaccatggg	2040
gaatgttcgg	ttgctagtag	ctacaaaacc	agcaaaacag	attcgatttg	tccatcacga	2100
gtccgtgcaa	tgctagcatc	ccgagcatgc	agatcatctg	tgatgatcgg	agatccactc	2160
agaaaaaacg	aatgcagaa	gatagtagaa	cacttggcag	atctcgaatc	tccttggaat	2220
tgcccacacg	gacgaccaac	aatgcgtcat	cttgtggact	tgacaacttt	actcacatta	2280
cctgatgacg	acaatgtcaa	tgatgatgat	gatgatgatg	caaccatctc	attggcatga	2340

<210> 5

<211> 402

<212> DNA

<213> Human sapiens

<400> 5

atggagcgag	ctgagagctc	gagtacagaa	cctgctaagg	ccatcaaacc	tattgatcgg	60
aagtcagtc	atcagatttg	ctctgggcag	gtggactga	gtctaagcac	tgccgtaaa	120
gagttagtag	aaaacagtct	ggatgctggt	gccactaata	ttgatctaaa	gcttaaggac	180
tatggagtgg	atcttattga	agtttcagac	aatggatgtg	gggtagaaga	agaaaacttc	240
gaaggcttaa	ctctgaaaca	tcacacatct	aagattcaag	agtttgccga	cctaaactcag	300
gttgaactt	ttggctttcg	gggggaagct	ctgagctcac	tttgtgcact	gagcgatgtc	360
accatttcta	cctgccacgc	atcggcgag	gttgaactt	ag		402

<210> 6

<211> 441

<212> DNA

<213> Arabidopsis thaliana

<400> 6

atgcaaggag	attcttctcc	gtctccgacg	actactagct	ctcctttgat	aagacctata	60
aacagaaacg	taattcacag	aatctgttcc	ggcgaagtca	tcttagacct	ctcttcggcc	120
gtcaaggagc	ttgtcgagaa	tagtctcgac	gccggcgcca	ccagtataga	gattaacctc	180
cgagactacg	gcgaagacta	ttttcaggtc	attgacaatg	gttgtggcat	ttccccaacc	240
aatttcaagg	tttgtgtcca	aattctccga	agaacttttg	atgttcttgc	acttaagcat	300
catacttcta	aattagagga	tttcacagat	cttttgaatt	tgactactta	tggttttaga	360
ggagaagcct	tgagctctct	ctgtgcattg	ggaaatctca	ctgtggaaac	aagaacaaag	420
aatgagccag	ttgctacgct	c				441

<210> 7

<211> 27

<212> DNA

<213> Human sapiens

<400> 7

tctagacatg	gagcgagctg	agagctc	27
------------	------------	---------	----

<210> 8

<211> 27

<212> DNA

<213> Human sapiens

<400> 8

tctagaagtt	ccaaccttcg	ccgatgc	27
------------	------------	---------	----

<210> 9

<211> 737

<212> PRT

<213> Arabidopsis thaliana

<400> 9

Met	Ile	Asp	Asp	Ser	Ser	Leu	Thr	Ala	Glu	Met	Glu	Glu	Glu	Ser
1				5					10				15	

Pro Ala Thr Thr Ile Val Pro Arg Glu Pro Pro Lys Ile Gln Arg Leu
 20 25 30
 Glu Glu Ser Val Val Asn Arg Ile Ala Ala Gly Glu Val Ile Gln Arg
 35 40 45
 Pro Val Ser Ala Val Lys Glu Leu Val Glu Asn Ser Leu Asp Ala Asp
 50 55 60
 Ser Ser Ser Ile Ser Val Val Val Lys Asp Gly Glu Leu Lys Leu Ile
 65 70 75 80
 Gln Val Ser Asp Asp Gly His Gly Ile Arg Arg Glu Asp Leu Pro Ile
 85 90 95
 Leu Cys Glu Arg His Thr Thr Ser Lys Leu Thr Lys Phe Glu Asp Leu
 100 105 110
 Phe Ser Leu Ser Ser Met Gly Phe Arg Gly Glu Ala Leu Ala Ser Met
 115 120 125
 Thr Tyr Val Ala His Val Thr Val Thr Thr Ile Thr Lys Gly Gln Ile
 130 135 140
 His Gly Tyr Arg Val Ser Tyr Arg Asp Gly Val Met Glu His Glu Pro
 145 150 155 160
 Lys Ala Cys Ala Ala Val Lys Gly Thr Gln Ile Met Val Glu Asn Leu
 165 170 175
 Phe Tyr Asn Met Ile Ala Arg Arg Lys Thr Leu Gln Asn Ser Ala Asp
 180 185 190
 Asp Tyr Gly Lys Ile Val Asp Leu Ser Arg Met Ala Ile His Tyr
 195 200 205
 Asn Asn Val Ser Phe Ser Cys Arg Lys His Gly Ala Val Lys Ala Asp
 210 215 220
 Val His Ser Val Val Ser Pro Ser Arg Leu Asp Ser Ile Arg Ser Val
 225 230 235 240
 Tyr Gly Val Ser Val Ala Lys Asn Leu Met Lys Val Glu Val Ser Ser
 245 250 255
 Cys Asp Ser Ser Gly Cys Thr Phe Asp Met Glu Gly Phe Ile Ser Asn
 260 265 270
 Ser Asn Tyr Val Ala Lys Lys Thr Ile Leu Val Leu Phe Ile Asn Asp
 275 280 285
~~Arg Leu Val Glu Cys Ser Ala Leu Lys Arg Ala Ile Glu Ile Val Tyr~~
 290 295 300
 Ala Ala Thr Leu Pro Lys Ala Ser Lys Pro Phe Val Tyr Met Ser Ile
 305 310 315 320
 Asn Leu Pro Arg Glu His Val Asp Ile Asn Ile His Pro Thr Lys Lys
 325 330 335
 Glu Val Ser Leu Leu Asn Gln Glu Ile Ile Glu Met Ile Gln Ser
 340 345 350
 Glu Val Glu Val Lys Leu Arg Asn Ala Asn Asp Thr Arg Thr Phe Gln
 355 360 365
 Glu Gln Lys Val Glu Tyr Ile Gln Ser Thr Leu Thr Ser Gln Lys Ser
 370 375 380
 Asp Ser Pro Val Ser Gln Lys Pro Ser Gly Gln Lys Thr Gln Lys Val
 385 390 395 400
 Pro Val Asn Lys Met Val Arg Thr Asp Ser Ser Asp Pro Ala Gly Arg
 405 410 415
 Leu His Ala Phe Leu Gln Pro Lys Pro Gln Ser Leu Pro Asp Lys Val
 420 425 430
 Ser Ser Leu Ser Val Val Arg Ser Ser Val Arg Gln Arg Arg Asn Pro
 435 440 445
 Lys Glu Thr Ala Asp Leu Ser Ser Val Gln Glu Leu Ile Ala Gly Val
 450 455 460
 Asp Ser Cys Cys His Pro Gly Met Leu Glu Thr Val Arg Asn Cys Thr
 465 470 475 480
 Tyr Val Gly Met Ala Asp Asp Val Phe Ala Leu Val Gln Tyr Asn Thr
 485 490 495
 His Leu Tyr Leu Ala Asn Val Val Asn Leu Ser Lys Glu Leu Met Tyr
 500 505 510
 Gln Gln Thr Leu Arg Arg Phe Ala His Phe Asn Ala Ile Gln Leu Ser

515 520 525
 Asp Pro Ala Pro Leu Ser Glu Leu Ile Leu Leu Ala Leu Lys Glu Glu
 530 535 540
 Asp Leu Asp Pro Gly Asn Asp Thr Lys Asp Asp Leu Lys Glu Arg Ile
 545 550 555 560
 Ala Glu Met Asn Thr Glu Leu Leu Lys Glu Lys Ala Glu Met Leu Glu
 565 570 575
 Glu Tyr Phe Ser Val His Ile Asp Ser Ser Ala Asn Leu Ser Arg Leu
 580 585 590
 Pro Val Ile Leu Asp Gln Tyr Thr Pro Asp Met Asp Arg Val Pro Glu
 595 600 605
 Phe Leu Leu Cys Leu Gly Asn Asp Val Glu Trp Glu Asp Glu Lys Ser
 610 615 620
 Cys Phe Gln Gly Val Ser Ala Ala Ile Gly Asn Phe Tyr Ala Met His
 625 630 635 640
 Pro Pro Leu Leu Pro Asn Pro Ser Gly Asp Gly Ile Gln Phe Tyr Ser
 645 650 655
 Lys Arg Gly Glu Ser Ser Gln Glu Lys Ser Asp Leu Glu Gly Asn Val
 660 665 670
 Asp Met Glu Asp Asn Leu Asp Gln Asp Leu Leu Ser Asp Ala Glu Asn
 675 680 685
 Ala Trp Ala Gln Arg Glu Trp Ser Ile Gln His Val Leu Phe Pro Ser
 690 695 700
 Met Arg Leu Phe Leu Lys Pro Pro Ala Ser Met Ala Ser Asn Gly Thr
 705 710 715 720
 Phe Val Lys Val Ala Ser Leu Glu Lys Leu Tyr Lys Ile Phe Glu Arg
 725 730 735
 Cys

<210> 10
 <211> 1151
 <212> PRT
 <213> Arabidopsis thaliana

<400> 10
 Met Lys Thr Ile Lys Pro Leu Pro Glu Gly Val Arg His Ser Met Arg
 1 5 10 15
 Ser Gly Ile Ile Met Phe Asp Met Ala Arg Val Val Glu Glu Leu Val
 20 25 30
 Phe Asn Ser Leu Asp Ala Gly Ala Thr Lys Val Ser Ile Phe Val Gly
 35 40 45
 Val Val Ser Cys Ser Val Lys Val Val Asp Asp Gly Ser Gly Val Ser
 50 55 60
 Arg Asp Asp Leu Val Leu Glu Gly Glu Arg Tyr Ala Thr Ser Lys Phe
 65 70 75 80
 His Asp Phe Thr Asn Val Glu Thr Ala Ser Glu Thr Phe Gly Phe Arg
 85 90 95
 Gly Glu Ala Leu Ala Ser Ile Ser Asp Ile Ser Leu Leu Glu Val Arg
 100 105 110
 Thr Lys Ala Ile Gly Arg Pro Asn Gly Tyr Arg Lys Val Met Lys Gly
 115 120 125
 Ser Lys Cys Leu His Leu Gly Ile Asp Asp Asp Arg Lys Asp Ser Gly
 130 135 140
 Thr Thr Val Thr Val Arg Asp Leu Phe Tyr Ser Gln Pro Val Arg Arg
 145 150 155 160
 Lys Tyr Met Gln Ser Ser Pro Lys Lys Val Leu Glu Ser Ile Lys Lys
 165 170 175
 Cys Val Phe Arg Ile Ala Leu Val His Ser Asn Val Ser Phe Ser Val
 180 185 190
 Leu Asp Ile Glu Ser Asp Glu Glu Phe Gln Thr Asn Pro Ser Ser
 195 200 205
 Ser Ala Phe Ser Leu Leu Met Arg Asp Ala Gly Thr Glu Ala Val Asn

210	215	220
Ser Leu Cys Lys Val	Asn Val Thr Asp Gly Met	Leu Asn Val Ser Gly
225	230	235
Phe Glu Cys Ala Asp	Asp Trp Lys Pro Thr Asp	Gly Gln Gln Thr Gly
245	250	255
Arg Arg Asn Arg Leu	Gln Ser Asn Pro Gly Tyr Ile	Leu Cys Ile Ala
260	265	270
Cys Pro Arg Arg Leu	Tyr Glu Phe Glu Pro Ser	Lys Thr His
275	280	285
Val Glu Phe Lys Lys	Trp Gly Pro Val Leu Ala	Phe Ile Glu Arg Ile
290	295	300
Thr Leu Ala Asn Trp	Lys Lys Asp Arg Ile Leu	Glu Leu Phe Asp Gly
305	310	315
Gly Ala Asp Ile Leu	Ala Lys Gly Asp Arg Gln	Asp Leu Ile Asp Asp
325	330	335
Lys Ile Arg Leu Gln	Asn Gly Ser Leu Phe Ser	Ile Leu His Phe Leu
340	345	350
Asp Ala Asp Trp Pro	Glu Ala Met Glu Pro Ala	Lys Lys Lys Leu Lys
355	360	365
Arg Ser Asn Asp His	Ala Pro Cys Ser Ser Leu	Leu Phe Pro Ser Ala
370	375	380
Asp Phe Lys Gln Asp	Gly Asp Tyr Phe Ser Pro	Arg Lys Asp Val Trp
385	390	395
Ser Pro Glu Cys Glu	Val Glu Leu Lys Ile Gln	Asn Pro Lys Glu Gln
405	410	415
Gly Thr Val Ala Gly	Phe Glu Ser Arg Thr Asp	Ser Leu Leu Gln Ser
420	425	430
Arg Asp Ile Glu Met	Gln Thr Asn Glu Asp Phe	Pro Gln Val Thr Asp
435	440	445
Leu Leu Glu Thr Ser	Leu Val Ala Asp Ser Lys	Cys Arg Lys Gln Phe
450	455	460
Leu Thr Arg Cys Gln	Ile Thr Thr Pro Val Asn	Ile Asn His Asp Phe
465	470	475
Met Lys Asp Ser Asp	Val Leu Asn Phe Gln Phe	Gln Gly Leu Lys Asp
485	490	495
Glu Leu Asp Val Ser	Asn Cys Ile Gly Lys His	Leu Leu Arg Gly Cys
500	505	510
Ser Ser Arg Val Ser	Leu Thr Phe His Glu Pro	Lys Leu Ser His Val
515	520	525
Glu Gly Tyr Glu Ser	Val Val Pro Met Ile Pro	Asn Glu Lys Gln Ser
530	535	540
Ser Pro Arg Val Leu	Glu Thr Arg Glu Gly Gly	Ser Tyr Cys Asp Val
545	550	555
Tyr Ser Asp Lys Thr	Pro Asp Cys Ser Leu Gly	Ser Ser Trp Gln Asp
565	570	575
Thr Asp Trp Phe Thr	Pro Gln Cys Ser Ser Asp	Arg Gly Cys Val Gly
580	585	590
Ile Gly Glu Asp Phe	Asn Ile Thr Pro Ile Asp	Thr Ala Glu Phe Asp
595	600	605
Ser Tyr Asp Glu Lys	Val Gly Ser Lys Lys Tyr	Leu Ser Ser Val Asn
610	615	620
Val Gly Ser Ser Val	Thr Gly Ser Phe Cys Leu	Ser Ser Glu Trp Ser
625	630	635
Pro Met Tyr Ser Thr	Pro Ser Ala Thr Lys	Trp Glu Ser Glu Tyr Gln
645	650	655
Lys Gly Cys Arg Ile	Leu Glu Gln Ser Leu Arg	Leu Gly Arg Met Pro
660	665	670
Asp Pro Glu Phe Cys	Phe Ser Ala Ala Asn	Asn Ile Lys Phe Asp His
675	680	685
Glu Val Ile Pro Glu	Met Asp Cys Cys Glu Thr	Gly Thr Asp Ser Phe
690	695	700
Thr Ala Ile Gln Asn	Cys Thr Gln Leu Ala Asp	Lys Ile Cys Lys Ser
705	710	715
		720

Ser Trp Gly His Ala Asp Asp Val Arg Ile Asp Gln Tyr Ser Ile Arg
 725 730 735
 Lys Glu Lys Phe Ser Tyr Met Asp Gly Thr Gln Asn Asn Ala Gly Lys
 740 745 750
 Gln Arg Ser Lys Arg Ser Arg Ser Ala Pro Pro Phe Tyr Arg Glu Lys
 755 760 765
 Lys Arg Phe Ile Ser Leu Ser Cys Lys Ser Asp Thr Lys Pro Lys Asn
 770 775 780
 Ser Asp Pro Ser Glu Pro Asp Asp Leu Glu Cys Leu Thr Gln Pro Cys
 785 790 795 800
 Asn Ala Ser Gln Met His Leu Lys Cys Ser Ile Leu Asp Asp Val Ser
 805 810 815
 Tyr Asp His Ile Gln Glu Thr Glu Lys Arg Leu Ser Ser Ala Ser Asp
 820 825 830
 Leu Lys Ala Ser Ala Gly Cys Arg Thr Val His Ser Glu Thr Gln Asp
 835 840 845
 Glu Asp Val His Glu Asp Phe Ser Ser Glu Glu Phe Leu Asp Pro Ile
 850 855 860
 Lys Ser Thr Thr Lys Trp Arg His Asn Cys Ala Val Ser Gln Val Pro
 865 870 875 880
 Lys Glu Ser His Glu Leu His Gly Gln Asp Gly Val Phe Asp Ile Ser
 885 890 895
 Ser Gly Leu Leu His Leu Arg Ser Asp Glu Ser Leu Val Pro Glu Ser
 900 905 910
 Ile Asn Arg His Ser Leu Glu Asp Ala Lys Val Leu Gln Gln Val Asp
 915 920 925
 Lys Lys Tyr Ile Pro Ile Val Ala Cys Gly Thr Val Ala Ile Val Asp
 930 935 940
 Gln His Ala Ala Asp Glu Arg Ile Arg Leu Glu Glu Leu Arg Thr Lys
 945 950 955 960
 Phe Ile Asn Asp Ala Leu Leu Ile Phe Val Leu Thr Leu Lys Val Leu
 965 970 975
 Pro Glu Met Gly Tyr Gln Leu Leu Gln Ser Tyr Ser Glu Gln Ile Arg
 980 985 990
 Asp Trp Gly Trp Ile Cys Asn Ile Thr Val Glu Gly Ser Thr Ser Phe
 995 1000 1005
 Lys Lys Asn Met Ser Ile Ile Gln Arg Lys Pro Thr Pro Ile Thr Leu
 1010 1015 1020
 Asn Ala Val Pro Cys Ile Leu Gly Val Asn Leu Ser Asp Val Asp Leu
 1025 1030 1035 1040
 Leu Glu Phe Leu Gln Gln Leu Ala Asp Thr Asp Gly Ser Ser Thr Ile
 1045 1050 1055
 Pro Pro Ser Val Leu Arg Val Leu Asn Ser Lys Ala Cys Arg Gly Ala
 1060 1065 1070
 Ile Met Phe Gly Asp Ser Leu Leu Pro Ser Glu Cys Ser Leu Ile Ile
 1075 1080 1085
 Asp Gly Leu Lys Gln Thr Ser Leu Cys Phe Gln Cys Ala His Gly Arg
 1090 1095 1100
 Pro Thr Thr Val Pro Leu Val Asp Leu Lys Ala Leu His Lys Gln Ile
 1105 1110 1115 1120
 Ala Lys Leu Ser Gly Arg Gln Val Trp His Gly Leu Gln Arg Arg Glu
 1125 1130 1135
 Ile Thr Leu Asp Arg Ala Lys Ser Arg Leu Asp Asn Ala Lys Ser
 1140 1145 1150

<210> 11

<211> 862

<212> PRT

<213> Homo sapiens

<400> 11

Met Glu Arg Ala Glu Ser Ser Ser Thr Glu Pro Ala Lys Ala Ile Lys
 1 5 10 15

Pro Ile Asp Arg Lys Ser Val His Gln Ile Cys Ser Gly Gln Val Val
 20 25 30
 Leu Ser Leu Ser Thr Ala Val Lys Glu Leu Val Glu Asn Ser Leu Asp
 35 40 45
 Ala Gly Ala Thr Asn Ile Asp Leu Lys Leu Lys Asp Tyr Gly Val Asp
 50 55 60
 Leu Ile Glu Val Ser Asp Asn Gly Cys Gly Val Glu Glu Glu Asn Phe
 65 70 75 80
 Glu Gly Leu Thr Leu Lys His His Thr Ser Lys Ile Gln Glu Phe Ala
 85 90 95
 Asp Leu Thr Gln Val Glu Thr Phe Gly Phe Arg Gly Glu Ala Leu Ser
 100 105 110
 Ser Leu Cys Ala Leu Ser Asp Val Thr Ile Ser Thr Cys His Ala Ser
 115 120 125
 Ala Lys Val Gly Thr Arg Leu Met Phe Asp His Asn Gly Lys Ile Ile
 130 135 140
 Gln Lys Thr Pro Tyr Pro Arg Pro Arg Gly Thr Thr Val Ser Val Gln
 145 150 155 160
 Gln Leu Phe Ser Thr Leu Pro Val Arg His Lys Glu Phe Gln Arg Asn
 165 170 175
 Ile Lys Lys Glu Tyr Ala Lys Met Val Gln Val Leu His Ala Tyr Cys
 180 185 190
 Ile Ile Ser Ala Gly Ile Arg Val Ser Cys Thr Asn Gln Leu Gly Gln
 195 200 205
 Gly Lys Arg Gln Pro Val Val Cys Thr Gly Gly Ser Pro Ser Ile Lys
 210 215 220
 Glu Asn Ile Gly Ser Val Phe Gly Gln Lys Gln Leu Gln Ser Leu Ile
 225 230 235 240
 Pro Phe Val Gln Leu Pro Pro Ser Asp Ser Val Cys Glu Glu Tyr Gly
 245 250 255
 Leu Ser Cys Ser Asp Ala Leu His Asn Leu Phe Tyr Ile Ser Gly Phe
 260 265 270
 Ile Ser Gln Cys Thr His Gly Val Gly Arg Ser Ser Thr Asp Arg Gln
 275 280 285
~~Phe Phe Phe Ile Asn Arg Arg Pro Cys Asp Pro Ala Lys Val Cys Arg~~
 290 295 300
 Leu Val Asn Glu Val Tyr His Met Tyr Asn Arg His Gln Tyr Pro Phe
 305 310 315 320
 Val Val Leu Asn Ile Ser Val Asp Ser Glu Cys Val Asp Ile Asn Val
 325 330 335
 Thr Pro Asp Lys Arg Gln Ile Leu Leu Gln Glu Glu Lys Leu Leu Leu
 340 345 350
 Ala Val Leu Lys Thr Ser Leu Ile Gly Met Phe Asp Ser Asp Val Asn
 355 360 365
 Lys Leu Asn Val Ser Gln Gln Pro Leu Leu Asp Val Glu Gly Asn Leu
 370 375 380
 Ile Lys Met His Ala Ala Asp Leu Glu Lys Pro Met Val Glu Lys Gln
 385 390 395 400
 Asp Gln Ser Pro Ser Leu Arg Thr Gly Glu Glu Lys Lys Asp Val Ser
 405 410 415
 Ile Ser Arg Leu Arg Glu Ala Phe Ser Leu Arg His Thr Thr Glu Asn
 420 425 430
 Lys Pro His Ser Pro Lys Thr Pro Glu Pro Arg Arg Ser Pro Leu Gly
 435 440 445
 Gln Lys Arg Gly Met Leu Ser Ser Thr Ser Gly Ala Ile Ser Asp
 450 455 460
 Lys Gly Val Leu Arg Pro Gln Lys Glu Ala Val Ser Ser Ser His Gly
 465 470 475 480
 Pro Ser Asp Pro Thr Asp Arg Ala Glu Val Glu Lys Asp Ser Gly His
 485 490 495
 Gly Ser Thr Ser Val Asp Ser Glu Gly Phe Ser Ile Pro Asp Thr Gly
 500 505 510
 Ser His Cys Ser Ser Glu Tyr Ala Ala Ser Ser Pro Gly Asp Arg Gly

515	Ser	Gln	Glu	His	Val	Asp	520	Ser	Gln	Glu	Lys	Ala	Pro	525	Glu	Thr	Asp	Asp
530	Ser	Phe	Ser	Asp	Val	Asp	535	Cys	His	Ser	Asn	Gln	Glu	540	Asp	Thr	Gly	Cys
545	Lys	Phe	Arg	Val	Leu	Pro	550	Gln	Pro	Thr	Asn	Leu	Ala	555	Thr	Pro	Asn	Thr
565	Lys	Arg	Phe	Lys	Glu	Glu	570	Ile	Leu	Ser	Ser	Ser	Asp	575	Ile	Cys	Gln	
580	Lys	Leu	Val	Asn	Thr	Gln	585	Asp	Met	Ser	Ala	Ser	Gln	590	Val	Asp	Val	Ala
595	Val	Lys	Ile	Asn	Lys	Lys	600	Val	Val	Pro	Leu	Asp	Phe	605	Ser	Met	Ser	Ser
610	Leu	Ala	Lys	Arg	Ile	Lys	615	Gln	Leu	His	His	Glu	Ala	620	Gln	Gln	Ser	Glu
625	Gly	Glu	Gln	Asn	Tyr	Arg	630	Lys	Phe	Arg	Ala	Lys	Ile	635	Cys	Pro	Gly	Glu
645	Asn	Gln	Ala	Ala	Glu	Asp	650	Glu	Leu	Arg	Lys	Glu	Ile	655	Ser	Lys	Thr	Met
660	Phe	Ala	Glu	Met	Glu	Ile	665	Ile	Gly	Gln	Phe	Asn	Leu	670	Gly	Phe	Ile	Ile
675	Thr	Lys	Leu	Asn	Glu	Asp	680	Ile	Phe	Ile	Val	Asp	Gln	685	His	Ala	Thr	Asp
690	Glu	Lys	Tyr	Asn	Phe	Glu	695	Met	Leu	Gln	Gln	His	Thr	700	Val	Leu	Gln	Gly
705	Gln	Arg	Leu	Ile	Ala	Pro	710	Gln	Thr	Leu	Asn	Leu	Thr	715	Ala	Val	Asn	Glu
725	Ala	Val	Leu	Ile	Glu	Asn	730	Leu	Glu	Ile	Phe	Arg	Lys	735	Asn	Gly	Phe	Asp
740	Phe	Val	Ile	Asp	Glu	Asn	745	Ala	Pro	Val	Thr	Glu	Arg	750	Ala	Lys	Leu	Ile
755	Ser	Leu	Pro	Thr	Ser	Lys	760	Asn	Trp	Thr	Phe	Gly	Pro	765	Gln	Asp	Val	Asp
770	Glu	Leu	Ile	Phe	Met	Leu	775	Ser	Asp	Ser	Pro	Gly	Val	780	Met	Cys	Arg	Pro
785	Ser	Arg	Val	Lys	Gln	Met	790	Phe	Ala	Ser	Arg	Ala	Cys	795	Arg	Lys	Ser	Val
805	Met	Ile	Gly	Thr	Ala	Leu	810	Asn	Thr	Ser	Glu	Met	Lys	815	Lys	Leu	Ile	Thr
820	His	Met	Gly	Glu	Met	Asp	825	His	Pro	Trp	Asn	Cys	Pro	830	His	Gly	Arg	Pro
835	Thr	Met	Arg	His	Ile	Ala	840	Asn	Leu	Gly	Val	Ile	Ser	845	Gln	Asn		
850							855							860				

<210> 12

<211> 779

<212> PRT

<213> Arabidopsis thaliana

<400> 12

Met	Gln	Gly	Asp	Ser	Ser	Pro	Ser	Pro	Thr	Thr	Thr	Ser	Ser	Pro	Leu
1				5					10					15	
Ile	Arg	Pro	Ile	Asn	Arg	Asn	Val	Ile	His	Arg	Ile	Cys	Ser	Gly	Gln
			20					25				30			
Val	Ile	Leu	Asp	Leu	Ser	Ser	Ala	Val	Lys	Glu	Leu	Val	Glu	Asn	Ser
		35				40						45			
Leu	Asp	Ala	Gly	Ala	Thr	Ser	Ile	Glu	Ile	Asn	Leu	Arg	Asp	Tyr	Gly
	50					55					60				
Glu	Asp	Tyr	Phe	Gln	Val	Ile	Asp	Asn	Gly	Cys	Gly	Ile	Ser	Pro	Thr
65				70					75					80	
Asn	Phe	Lys	Val	Cys	Val	Gln	Ile	Leu	Arg	Arg	Thr	Phe	Asp	Val	Leu
			85					90						95	
Ala	Leu	Lys	His	His	Thr	Ser	Lys	Leu	Glu	Asp	Phe	Thr	Asp	Leu	Leu

Asn	Leu	Thr	100	Thr	Tyr	Gly	Phe	Arg	105	Gly	Glu	Ala	Leu	Ser	110	Ser	Leu	Cys
			115					120							125			
Ala	Leu	Gly	Asn	Leu	Thr	Val	Glu	Thr	Arg	Thr	Lys	Asn	Glu	Pro	Val			
			130					135							140			
Ala	Thr	Leu	Leu	Thr	Phe	Asp	His	Ser	Gly	Leu	Leu	Thr	Ala	Glu	Lys			
145					150					155					160			
Lys	Thr	Ala	Arg	Gln	Ile	Gly	Thr	Thr	Val	Thr	Val	Arg	Lys	Leu	Phe			
				165					170						175			
Ser	Asn	Leu	Pro	Val	Arg	Ser	Lys	Glu	Phe	Lys	Arg	Asn	Ile	Arg	Lys			
			180					185						190				
Glu	Tyr	Gly	Lys	Leu	Val	Ser	Leu	Leu	Asn	Ala	Tyr	Ala	Leu	Ile	Ala			
			195					200						205				
Lys	Gly	Val	Arg	Phe	Val	Cys	Ser	Asn	Thr	Thr	Gly	Lys	Asn	Pro	Lys			
			210			215					220							
Ser	Val	Val	Leu	Asn	Thr	Gln	Gly	Arg	Gly	Ser	Leu	Lys	Asp	Asn	Ile			
225					230					235					240			
Ile	Thr	Val	Phe	Gly	Ile	Ser	Thr	Phe	Thr	Ser	Leu	Gln	Pro	Gly	Thr			
			245						250					255				
Gly	Arg	Asn	Leu	Ala	Asp	Arg	Gln	Tyr	Phe	Phe	Ile	Asn	Gly	Arg	Pro			
			260					265						270				
Val	Asp	Met	Pro	Lys	Val	Ser	Lys	Leu	Val	Asn	Glu	Leu	Tyr	Lys	Asp			
			275					280					285					
Thr	Ser	Ser	Arg	Lys	Tyr	Pro	Val	Thr	Ile	Leu	Asp	Phe	Ile	Val	Pro			
			290			295					300							
Gly	Gly	Ala	Cys	Asp	Leu	Asn	Val	Thr	Pro	Asp	Lys	Arg	Lys	Val	Phe			
305					310					315					320			
Phe	Ser	Asp	Glu	Thr	Ser	Val	Ile	Gly	Ser	Leu	Arg	Glu	Gly	Leu	Asn			
			325						330					335				
Glu	Ile	Tyr	Ser	Ser	Asn	Ala	Ser	Tyr	Ile	Val	Asn	Arg	Phe	Glu				
			340					345					350					
Glu	Asn	Ser	Glu	Gln	Pro	Asp	Lys	Ala	Gly	Val	Ser	Ser	Phe	Gln	Lys			
			355				360					365						
Lys	Ser	Asn	Leu	Leu	Ser	Glu	Gly	Ile	Val	Leu	Asp	Val	Ser	Ser	Lys			
			370			375					380							
Thr	Arg	Leu	Gly	Glu	Ala	Ile	Glu	Lys	Glu	Asn	Pro	Ser	Leu	Arg	Glu			
385					390					395					400			
Val	Glu	Ile	Asp	Asn	Ser	Ser	Pro	Met	Glu	Lys	Phe	Lys	Phe	Glu	Ile			
			405						410					415				
Lys	Ala	Cys	Gly	Thr	Lys	Lys	Gly	Glu	Gly	Ser	Leu	Ser	Val	His	Asp			
			420					425					430					
Val	Thr	His	Leu	Asp	Lys	Thr	Pro	Ser	Lys	Gly	Leu	Pro	Gln	Leu	Asn			
			435				440					445						
Val	Thr	Glu	Lys	Val	Thr	Asp	Ala	Ser	Lys	Asp	Leu	Ser	Ser	Arg	Ser			
			450			455					460							
Ser	Phe	Ala	Gln	Ser	Thr	Leu	Asn	Thr	Phe	Val	Thr	Met	Gly	Lys	Arg			
465					470					475				480				
Lys	His	Glu	Asn	Ile	Ser	Thr	Ile	Leu	Ser	Glu	Thr	Pro	Val	Leu	Arg			
			485						490					495				
Asn	Gln	Thr	Ser	Ser	Tyr	Arg	Val	Glu	Lys	Ser	Lys	Phe	Glu	Val	Arg			
			500					505					510					
Ala	Leu	Ala	Ser	Arg	Cys	Leu	Val	Glu	Gly	Asp	Gln	Leu	Asp	Asp	Met			
			515				520					525						
Val	Ile	Ser	Lys	Glu	Asp	Met	Thr	Pro	Ser	Glu	Arg	Asp	Ser	Glu	Leu			
			530			535					540							
Gly	Asn	Arg	Ile	Ser	Pro	Gly	Thr	Gln	Ala	Asp	Asn	Val	Glu	Arg	His			
545					550					555					560			
Glu	Arg	Val	Leu	Gly	Gln	Phe	Asn	Leu	Gly	Phe	Ile	Ile	Ala	Lys	Leu			
			565						570					575				
Glu	Arg	Asp	Leu	Phe	Ile	Val	Asp	Gln	His	Ala	Ala	Asp	Glu	Lys	Phe			
			580					585					590					
Asn	Phe	Glu	His	Leu	Ala	Arg	Ser	Thr	Val	Leu	Asn	Gln	Gln	Pro	Leu			
			595				600						605					

Leu Gln Pro Leu Asn Leu Glu Leu Ser Pro Glu Glu Glu Val Thr Val
 610 615 620
 Leu Met His Met Asp Ile Ile Arg Glu Asn Gly Phe Leu Leu Glu Glu
 625 630 635 640
 Asn Pro Ser Ala Pro Gly Lys His Phe Arg Leu Arg Ala Ile Pro
 645 650 655
 Tyr Ser Lys Asn Ile Thr Phe Gly Val Glu Asp Leu Lys Asp Leu Ile
 660 665 670
 Ser Thr Leu Gly Asp Asn His Gly Glu Cys Ser Val Ala Ser Ser Tyr
 675 680 685
 Lys Thr Ser Lys Thr Asp Ser Ile Cys Pro Ser Arg Val Arg Ala Met
 690 695 700
 Leu Ala Ser Arg Ala Cys Arg Ser Ser Val Met Ile Gly Asp Pro Leu
 705 710 715 720
 Arg Lys Asn Glu Met Gln Lys Ile Val Glu His Leu Ala Asp Leu Glu
 725 730 735
 Ser Pro Trp Asn Cys Pro His Gly Arg Pro Thr Met Arg His Leu Val
 740 745 750
 Asp Leu Thr Thr Leu Leu Thr Leu Pro Asp Asp Asp Asn Val Asn Asp
 755 760 765
 Asp Asp Asp Asp Ala Thr Ile Ser Leu Ala
 770 775

<210> 13
 <211> 133
 <212> PRT
 <213> Homo sapiens

<400> 13
 Met Glu Arg Ala Glu Ser Ser Ser Thr Glu Pro Ala Lys Ala Ile Lys
 1 5 10 15
 Pro Ile Asp Arg Lys Ser Val His Gln Ile Cys Ser Gly Gln Val Val
 20 25 30
 Leu Ser Leu Ser Thr Ala Val Lys Glu Leu Val Glu Asn Ser Leu Asp
 35 40 45
 Ala Gly Ala Thr Asn Ile Asp Leu Lys Leu Lys Asp Tyr Gly Val Asp
 50 55 60
 Leu Ile Glu Val Ser Asp Asn Gly Cys Gly Val Glu Glu Glu Asn Phe
 65 70 75 80
 Glu Gly Leu Thr Leu Lys His His Thr Ser Lys Ile Gln Glu Phe Ala
 85 90 95
 Asp Leu Thr Gln Val Glu Thr Phe Gly Phe Arg Gly Glu Ala Leu Ser
 100 105 110
 Ser Leu Cys Ala Leu Ser Asp Val Thr Ile Ser Thr Cys His Ala Ser
 115 120 125
 Ala Lys Val Gly Thr
 130

<210> 14
 <211> 147
 <212> PRT
 <213> Arabidopsis thaliana

<400> 14
 Met Gln Gly Asp Ser Ser Pro Ser Pro Thr Thr Thr Ser Ser Pro Leu
 1 5 10 15
 Ile Arg Pro Ile Asn Arg Asn Val Ile His Arg Ile Cys Ser Gly Gln
 20 25 30
 Val Ile Leu Asp Leu Ser Ser Ala Val Lys Glu Leu Val Glu Asn Ser
 35 40 45
 Leu Asp Ala Gly Ala Thr Ser Ile Glu Ile Asn Leu Arg Asp Tyr Gly
 50 55 60
 Glu Asp Tyr Phe Gln Val Ile Asp Asn Gly Cys Gly Ile Ser Pro Thr

WO 01/61012

PCT/US00/35397

65					70				75				80		
Asn	Phe	Lys	Val	Cys	Val	Gln	Ile	Leu	Arg	Arg	Thr	Phe	Asp	Val	Leu
				85					90					95	
Ala	Leu	Lys	His	His	Thr	Ser	Lys	Leu	Glu	Asp	Phe	Thr	Asp	Leu	Leu
			100					105					110		
Asn	Leu	Thr	Thr	Tyr	Gly	Phe	Arg	Gly	Glu	Ala	Leu	Ser	Ser	Leu	Cys
		115					120					125			
Ala	Leu	Gly	Asn	Leu	Thr	Val	Glu	Thr	Arg	Thr	Lys	Asn	Glu	Pro	Val
	130					135					140				
Ala	Thr	Leu													
145															

INTERNATIONAL SEARCH REPORT

International Application No
PLI/US 00/35397

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/29 C12N15/82 C12N5/10 C12Q1/68 C07K14/415
A01H5/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K C12N C12Q A01H

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 19492 A (BETZNER ANDREAS STEFAN ;DOUTRIAUX MARIE PASCALE (FR); PEREZ PASCAL) 22 April 1999 (1999-04-22)	86, 91-105
Y	the whole document	1-90, 106-114
Y	--- NICOLAIDES NICHOLAS C ET AL: "A naturally occurring hPMS2 mutation can confer a dominant negative mutator phenotype." MOLECULAR AND CELLULAR BIOLOGY, vol. 18, no. 3, March 1998 (1998-03), pages 1635-1641, XP002165242 ISSN: 0270-7306 the whole document, esp. p.1641, first paragraph --- -/--	1-90, 106-114

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

12 April 2001

Date of mailing of the international search report

09.07.01

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Kania, T

INTERNATIONAL SEARCH REPORT

Inter al Application No
PC1/US 00/35397

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 97 05268 A (SETRATECH ;WIND NIELS DE (NL); DEKKER-VLAAR HELENA MARIA JOHA (NL)) 13 February 1997 (1997-02-13) see the whole document; esp. claim 5	87-90
A	--- K M CULLIGAN AND J B HAYS: "DNA mismatch repair in plants" PLANT PHYSIOLOGY, AMERICAN SOCIETY OF PLANT PHYSIOLOGISTS, ROCKVILLE, MD, US, vol. 115, 1997, pages 833-839, XP002099372 ISSN: 0032-0889 cited in the application the whole document	1-114
A	--- LIPKIN STEVEN M ET AL: "MLH3: A DNA mismatch repair gene associated with mammalian microsatellite instability." NATURE GENETICS, vol. 24, no. 1, January 2000 (2000-01), pages 27-35, XP002165243 ISSN: 1061-4036 page 33, left-hand column, line 8 - line 18	1-86, 89, 90, 106-112
A	--- JEAN M ET AL: "Isolation and characterization of AtMLH1, a MutL homologue from Arabidopsis thaliana." MOLECULAR AND GENERAL GENETICS, vol. 262, no. 4-5, December 1999 (1999-12), pages 633-642, XP000986138 ISSN: 0026-8925 the whole document -----	1-114

INTERNATIONAL SEARCH REPORT

II International application No.
PCT/US 00/35397

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-114

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-114

Methods for making hypermutable plants cells by introducing a polynucleotide comprising a dominant-negative allele of a mismatch repair gene into the cell, whereby the cell becomes hypermutable. Said method as embodied in the claims, and homogeneous compositions of hypermutable plant cells generated by said method.

A hypermutable transgenic plant wherein at least 50% of the cells comprise a dominant-negative allele of a mismatch repair gene, said gene as embodied in the claims.

A method of generating a mutation in a gene of interest in a plant cell or a plant comprising the steps of: growing a hypermutable plant cell or plant comprising the gene of interest and a dominant-negative allele of a mismatch repair gene, testing the plant cell or plant to determine whether the gene of interest harbors a mutation. Said step of testing as embodied in the claims. A hypermutable plant made by said method and as embodied in the claims.

A method for generating a hypermutable plant comprising the steps of: inhibiting endogenous mismatch repair activity of a plant, whereby the plant becomes hypermutable. Said step of inhibiting and the mismatch repair sequences used as embodied in the claims.

A vector for introducing a dominant-negative allele of a mismatch repair gene into a plant comprising: a dominant-negative allele of a mismatch repair gene under the transcriptional control of a promoter which is functional in a plant. Said vector as embodied in the claims.

2. Claims: 115-121

A vector for introducing a dominant-negative allele of a mismatch repair gene into a plant comprising: a dominant-negative allele of a mismatch repair gene under the transcriptional control of a promoter which is functional in a plant. Said vector wherein the allele of the mismatch repair gene is Arabidopsis PMS134.

An isolated and purified polynucleotide encoding Arabidopsis PMS2 as shown in SEQ ID NO:14, and comprising the sequence as shown in SEQ ID NO:4.

An isolated and purified polynucleotide encoding Arabidopsis PMS134 as shown in SEQ ID NO:16, and comprising the sequence as shown in SEQ ID NO:6.

Isolated and purified proteins which are Arabidopsis PMS2 and PMS134 as shown in SEQ ID NOs:14,16.

3. Claim : 122

A method for determining the presence of a mismatch repair

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

defect in a plant or a plant cell, comprising: comparing at least two microsatellite markers in test cells or a test plant to the at least two markers in cells of a normal plant, identifying the test cells or test plant as having a mismatch repair defect if at least two markers are found to be rearranged relative to the cells of a normal plant. Said method as embodied in the claims.

INTERNATIONAL SEARCH REPORT
 Information on patent family members

International Application No
 PCT/US 00/35397

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9919492 A	22-04-1999	AU 1157399 A EP 1027447 A ZA 9809242 A	03-05-1999 16-08-2000 15-04-1999
WO 9705268 A	13-02-1997	AU 4784996 A EP 0842289 A	26-02-1997 20-05-1998